

Pseudomonas aeruginosa Population Structure Revisited

Jean-Paul Pirnay^{1*}, Florence Bilocq¹, Bruno Pot², Pierre Cornelis³, Martin Zizi⁴, Johan Van Eldere⁵, Pieter Deschaght⁶, Mario Vanechoutte⁶, Serge Jennes¹, Tyrone Pitt⁷, Daniel De Vos^{1,3}

1 Laboratory for Molecular and Cellular Technology, Burn Centre, Queen Astrid Military Hospital, Brussel, Belgium, **2** Applied Maths, Sint-Martens-Latem, Belgium, **3** Laboratory of Microbial Interactions, Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute of Biotechnology, Vrije Universiteit Brussel, Brussel, Belgium, **4** Department of Physiology, Vrije Universiteit Brussel, Brussel, Belgium, **5** Rega Institute and Laboratory of Microbiology, Gasthuisberg University Hospital, Catholic University of Leuven, Leuven, Belgium, **6** Laboratory for Bacteriology Research, Department of Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium, **7** Laboratory of Healthcare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, London, United Kingdom

Abstract

At present there are strong indications that *Pseudomonas aeruginosa* exhibits an epidemic population structure; clinical isolates are indistinguishable from environmental isolates, and they do not exhibit a specific (disease) habitat selection. However, some important issues, such as the worldwide emergence of highly transmissible *P. aeruginosa* clones among cystic fibrosis (CF) patients and the spread and persistence of multidrug resistant (MDR) strains in hospital wards with high antibiotic pressure, remain contentious. To further investigate the population structure of *P. aeruginosa*, eight parameters were analyzed and combined for 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on five continents, from diverse clinical (human and animal) and environmental habitats. The analysed parameters were: i) O serotype, ii) Fluorescent Amplified-Fragment Length Polymorphism (FALFP) pattern, nucleotide sequences of outer membrane protein genes, iii) *oprI*, iv) *oprL*, v) *oprD*, vi) pyoverdine receptor gene profile (*fpvA* type and *fpvB* prevalence), and prevalence of vii) exoenzyme genes *exoS* and *exoU* and viii) group I pilin glycosyltransferase gene *tfpO*. These traits were combined and analysed using biological data analysis software and visualized in the form of a minimum spanning tree (MST). We revealed a network of relationships between all analyzed parameters and non-congruence between experiments. At the same time we observed several conserved clones, characterized by an almost identical data set. These observations confirm the nonclonal epidemic population structure of *P. aeruginosa*, a superficially clonal structure with frequent recombinations, in which occasionally highly successful epidemic clones arise. One of these clones is the renowned and widespread MDR serotype O12 clone. On the other hand, we found no evidence for a widespread CF transmissible clone. All but one of the 43 analysed CF strains belonged to a ubiquitous *P. aeruginosa* "core lineage" and typically exhibited the *exoS*⁺/*exoU*⁻ genotype and group B *oprL* and *oprD* alleles. This is to our knowledge the first report of an MST analysis conducted on a polyphasic data set.

Citation: Pirnay J-P, Bilocq F, Pot B, Cornelis P, Zizi M, et al. (2009) *Pseudomonas aeruginosa* Population Structure Revisited. PLoS ONE 4(11): e7740. doi:10.1371/journal.pone.0007740

Editor: Niyaz Ahmed, University of Hyderabad, India

Received: July 27, 2009; **Accepted:** September 26, 2009; **Published:** November 13, 2009

Copyright: © 2009 Pirnay et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grant WB15 of the Royal High Institute for Defence (RHID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Dr. Pot is affiliated with Applied Maths. Applied Maths played no role in the funding of the research.

* E-mail: jean-paul.pirnay@mail.be

Introduction

In his 1882 paper, "Sur les colorations bleue et verte des linges à pansements", introduced by Louis Pasteur, Carle Gessard describes the isolation of an organism causing a blue-green coloration of wound dressings [1]. He describes this 'accidental' organism as colourless, globular, 1 to 1.5 thousandths of a millimetre in length, aerobic and very motile. The bacterium was named *Bacillus* (rod) *pyocyaneus*. Today we refer to this organism as *Pseudomonas aeruginosa*. This species is ubiquitous in the biosphere, has wide metabolic versatility and high intrinsic and acquired resistance to antimicrobials. It can be found in a wide variety of ecological environments ranging from fresh and salt water to the rhizosphere in which they colonize the endemic fauna (e.g. nematodes), flora and fungi (e.g. *Pythium* spp.) [2]. The opportunistic bacterium *P. aeruginosa* occasionally migrates from its natural environment and causes disease in animals (wild, domestic and livestock) and humans. In the latter it has emerged,

partly due to its intrinsic antibiotic resistance, as a major pathogen in the airways of cystic fibrosis (CF) patients, causing often-fatal chronic respiratory infections, and as one of the most clinically significant opportunist nosocomial agents. Immunosuppressed patients such as those with severe burns, cancer or AIDS are particularly at risk.

Numerous research groups have demonstrated that *P. aeruginosa* clinical isolates are genotypically, chemotaxonomically, and functionally indistinguishable from environmental isolates. Römling *et al.* observed that the most frequently identified clone in CF patients was also detected at a relatively high frequency in aquatic environments [3] and Rahme *et al.* demonstrated the infectivity of a *P. aeruginosa* strain in both plant and animal models [4]. Similarly, *P. aeruginosa* strains isolated from a gasoline-contaminated aquifer were indistinguishable from clinical isolates [5] and both oil-contaminated soil isolates and clinical isolates showed pathogenic and biodegradative properties [6].

Population structure

Using multilocus enzyme electrophoresis, Maynard Smith and colleagues demonstrated that bacterial population structures could range from panmictic or fully sexual, with random association between alleles, to clonal, with nonrandom association of alleles, the latter resulting in the frequent recovery of relatively few of the many possible multilocus genotypes [7]. An intermediate type of population structure that is predominantly sexual, but harbours some epidemic clones, which show significant association between loci, was called ‘epidemic’.

The population structure of *P. aeruginosa* has been the subject of numerous investigations, we present an overview. Both Denamur *et al.* in 1993, and Picard *et al.* in 1994, suggested a panmictic population structure for the species but highlighted the need for caution in inferring the population structure from any single class of genetic marker [8,9]. In 2000, comparative sequencing of 19 environmental and clinical isolates revealed a net-like population with a high frequency of recombination between isolates [10]. Using randomly amplified polymorphic DNA typing, Ruimy *et al.* demonstrated that bacteremia and pneumonia were not caused by specific *P. aeruginosa* clones [11]. In 2001 Lomholt and colleagues suggested an epidemic population structure for a *P. aeruginosa* population isolated mainly from patients with keratitis and their environment [12]. They found evidence for an epidemic clone that is pathogenic to the eye and is characterized by a distinct combination of virulence factors. In 2002, we combined the data obtained by 4 different typing methods, performed on a batch of 73 unrelated clinical and environmental *P. aeruginosa* isolates, collected across the world and observed a clear mosaicism in the results and a non-congruence between experiments, features of a panmictic population structure [13]. But, in this network we also observed some clonal complexes characterized by an almost identical data set. There was no obvious correlation between these dominant clones and habitat or, with the exception of some recent clones, their geographical origin. Therefore, we suggested an epidemic population structure for *P. aeruginosa*. Using multi locus sequence typing (MLST), Curran *et al.* confirmed in 2004 that *P. aeruginosa* exhibits a nonclonal epidemic population structure [14]. The *P. aeruginosa* population in the River Woluwe in Brussels was found to be almost as diverse as the global population, harbouring members of nearly all successful clonal complexes [15].

Several groups found that *P. aeruginosa* possessed a highly conserved genome, which encoded genes important for survival in numerous environments including humans and evolved through the acquisition, loss, and reorganisation of genome islands and genome islets [16–20]. Horizontal gene transfer (HGT) might play a more important role than point mutation in the adaptation of *P. aeruginosa* to different habitats. Despite not believed to be naturally competent, *P. aeruginosa* displays a high level of interstrain genomic plasticity and contains a high number of unfixed genes. Shen *et al.* put forward the idea of a population-based supra-genome that is substantially larger than the genome size of any of the component strains [21]. No two strains would be identical in terms of their genetic content and HGT continuously creates new strains with unique genetic characteristics.

Environmentally endemic bacteriophages are probably responsible for a fair amount of HGT, as they were shown to be formidable transducers of naturally occurring microbial communities of *P. aeruginosa* [22].

In 2006 Lee and colleagues tested the pathogenicity of diverse *P. aeruginosa* strains in a *Caenorhabditis elegans* pathogenicity model and showed that genes required for pathogenicity in one strain of *P. aeruginosa* were neither required for, nor predictive of virulence in other strains [23]. They concluded that virulence in *P. aeruginosa* is

both multifactorial and combinatorial, the result of a pool of pathogenicity-related genes that interact in various combinations in different backgrounds.

In 2007 Wiehlmann and colleagues analysed 240 *P. aeruginosa* strains with a DNA array tube assay and reported the segregation of strains from diverse habitats and geographic origin into two large nonoverlapping clusters and 45 isolated clonal complexes composed of a few or even single strains [24]. The majority of strains belonged to a few dominant clones widespread in disease and environmental habitats.

In conclusion, there appears to be a consensus that the *P. aeruginosa* population structure is nonclonal epidemic, that clinical isolates are indistinguishable from environmental isolates, and that there are no specific clones with a specific (disease) habitat selection. The *P. aeruginosa* genome consists of a highly conserved core spiked with mobile islands and elements, which are exchanged between strains through intensive and basically phage-mediated HGT, thus creating the striking diversity of this ubiquitous opportunistic pathogen.

Despite the above-mentioned studies, some important contentious issues remain. First, since the 1980s several studies have reported the emergence, spread and persistence of multidrug resistant (MDR) clones in hospitals, mainly in intensive care wards with high antibiotic pressure. Two serotypes, O11 and O12, are highly associated with these epidemic strains [25–47]. Typing of these strains supported a heterogeneous population in serotype O11 but those of serotype O12 often appeared to lack significant diversity.

Second, since the second half of the 1990s, an increasing number of *P. aeruginosa* ‘transmissible’ CF clones have been reported worldwide [48–60], suggestive of an emergence of specific clones that have adapted to the CF airway environment and are spreading within CF populations.

This study

To provide a reference evolutionary framework and to position these emergent *P. aeruginosa* clones in the global population structure, we decided to expand our earlier study [13] both in terms of number and range of isolates and of characters investigated. Our starting material consisted of a collection of 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on 5 continents, including isolates from diverse clinical (human and animal) and environmental habitats (Table 1).

Since different (genetic) markers have been shown to measure different evolutionary forces, confirming the importance of a polyphasic approach to population analysis [8,9,19,61,62], we decided to analyse and combine data from eight parameters that are equally dispersed over the *P. aeruginosa* genome (Table 2). The parameters investigated were i) O-serotype, ii) total genome profile by fluorescent amplified-fragment length polymorphism (FAFLP) analysis, nucleotide sequence of the outer membrane protein genes iii) *oprI*, iv) *oprL*, and v) *oprD*, vi) pyoverdine receptor gene profile (*fpvA* type and *fpvB* prevalence), and the prevalence of vii) exoenzyme genes *exoS* and *exoU* and viii) group I pilin glycosyltransferase gene *tfpO*.

Serotyping only allows for a crude discrimination between different *P. aeruginosa* isolates, but because it has been performed all over the world for more than 80 years [63] it forms a bridge between old and new epidemiological studies.

FAFLP is a highly discriminatory and reproducible genotyping method based on the selective amplification of a subset of DNA fragments generated by restriction enzyme digestion [64–66].

Table 1. Origin of the *P. aeruginosa* strains (summary).

Locality	Country	CF	Clinical non CF	Animal	Environment	Hospital environment	Unknown
Buenos Aires	Argentina		1				
Hobart	Australia	2	15		2	1	
Melbourne	Australia	1	1				
Antwerp	Belgium	2					
Brussels	Belgium	9	13		13	6	
De Haan Holiday Camp	Belgium	4					
Geel	Belgium		1				
Ghent	Belgium	5	4		1		
Leuven	Belgium	3	2				
North sea	Belgium				1		
Cotonu	Benin				1		
Sofia	Bulgaria		5			1	
Vancouver	Canada	2					
Chengdu	China						1
Cali	Colombia		3			1	
Prague	Czech Republic		1			2	1
Lwiro	Democratic Republic of Congo		2				
Nantes	France		1				
Paris	France		14	1			
Tbilisi	Georgian Republic		2				
Hanover	Germany	7				2	
Mulheim	Germany				2		
Ruhr River	Germany				1		
Aachen	Germany		3				
Athens	Greece		5				
Budapest	Hungary		3				2
IDEXX Laboratories	India			11			
Pordenone	Italy		1				
Lake Tamako	Japan				2		
Otshuchi Bay	Japan			1			
Pacific Ocean	Japan				10		
Sagami Bay	Japan				3		
Zenpukujii Pond	Japan				1		
Arakawa River	Japan				2		
Suruga Bay	Japan				2		
Loltun	Mexico				1		
Karachi	Pakistan				2		
Panama City	Panama		10				
Lisbon	Portugal	4	1				
Veterinary	Portugal			35			
Canas	Puerto Rico				1		
Unknown	Puerto Rico				1		
Bucarest	Roumania		7		1		1
Beverwijk	The Netherlands		4				
Holiday Camps	The Netherlands	1					
Rotterdam	The Netherlands		1				
Tacloban City	The Philippines		1				
Unknown	The Philippines				1		
Mediterranean sea	Tunisia				1		
Tunis	Tunisia		3				

Table 1.Cont.

Locality	Country	CF	Clinical non CF	Animal	Environment	Hospital environment	Unknown
Istanbul	Turkey	6					
Birmingham	UK	1					
Cambridge	UK				1		
Colindale	UK	1					
Elstree	UK	3					
IDEXX Laboratories	UK			10			
Liverpool	UK	1					
London	UK	9					
Manchester	UK	1					
NIMR	UK						2
Roehampton	UK	1					
Surrey	UK	1					
Ann Arbor	US	3					
Boston	US	5					
California	US						2
Detroit	US						1
Jekyll Island	US			5	5		
Kentucky	US						2
San Antonio	US	9					
69 localities	30 countries (5 continents)	43	142	63	55	13	12

doi:10.1371/journal.pone.0007740.t001

Although it is generally assumed that the best means of indexing natural variation in a population structure is to sequence housekeeping genes [67] we previously showed that the DNA sequence of the *oprI*, *oprL* and *oprD* genes generated equally discriminative data [13]. The *oprI* and *oprL* genes, which code for outer membrane lipoproteins [68–71], showed sequence diversity comparable to that of housekeeping genes [13] and have been included in SNP schemes [19].

The *P. aeruginosa oprD* gene codes for a specialized pore protein, OprD, which allows selective permeation of basic amino acids and their structural analogs like the carbapenem antibiotics imipenem

and meropenem [72,73]. It exhibits important sequence variability with multiple non-silent mutations and a microscale mosaic structure resulting from multiple recombinational events [74]. The *oprD* sequence data have proven to be an extremely interesting genetic marker, for the following reasons: (i) resistance to carbapenems is often achieved by defective *oprD* mutations (DOMs), (ii) the mosaic structure of the *oprD* gene exposes evidence of recombination events between *P. aeruginosa* strains, (iii) the virtually unlimited number of *oprD* alleles provides high discriminatory power, (iv) despite this extremely high sequence variability, members of narrow clonal complexes often show identical *oprD* sequences, thus illustrating the stability of these complexes [13].

Pyoverdines are high-affinity fluorescent peptidic siderophores secreted by *P. aeruginosa* in order to scavenge Fe(III) in the extracellular environment and shuttle it into the cell [75]. Uptake of the pyoverdine-Fe(III) complex is mediated by FpvA, a specific outer membrane receptor protein. Three *P. aeruginosa* siderovars can be distinguished, each producing a different pyoverdine (type I, II and III) and a matching cognate FpvA receptor [76–78]. The type II pyoverdine receptors are more diverse and it has been suggested that they are under positive selection [79–80]. Two distinct type II pyoverdine receptor gene clusters were observed: IIa and IIb [81]. In 2004, an additional pyoverdine receptor, FpvB, was discovered [82]. It was found to confer, in pyoverdine type II and III producing *P. aeruginosa* strains, the capacity to utilize type I pyoverdine as a source of iron. The majority of *P. aeruginosa* strains were shown to possess the *fpvB* gene.

ExoS and ExoU are effector molecules (exoenzymes) that can be injected directly into the host cell by the type III secretion system. There are indications that ExoS is the major cytotoxin required for colonization and dissemination during infection, while secretion of ExoU has been associated with increased virulence [83,84].

Table 2. Genomic localisation of the parameters investigated in this study.

Gene	Genomic localization (Mb)*
<i>oprD</i>	~1.04
<i>oprL</i>	~1.06
<i>fpvA</i>	~2.66
<i>oprI</i>	~3.21
Serotype (<i>wbpM-himD</i>)	~3.53
<i>exoS</i>	~4.30
<i>exoU</i>	~4.58
<i>fpvB</i>	~4.66
<i>tfpO (pilO)</i>	~5.07

*Localisation in the genome of reference strain PAO1 (reference strain UCBPP-PA14 for *exoU*) according to the *Pseudomonas aeruginosa* Genome Database (<http://www.pseudomonas.com>).

doi:10.1371/journal.pone.0007740.t002

The pilin glycosyltransferase TfpO (also called PilO) is an inner membrane protein that captures O antigen subunits and attaches them to a serine residue at the carboxy terminus of the group I pilins [85]. The group I pilin-containing strains can be divided into subgroups: TfpOa (pilin group Ia) strains and TfpOb (pilin group Ib) strains. Analysis of pilin allele distribution among isolates from various sources revealed a striking bias in the prevalence of isolates with group I pilin genes from CF compared with non-CF human sources, suggesting that this particular pilin type may confer a colonization or persistence advantage in the CF host [86].

The above-described traits were combined and analysed using biological data analysis software. The results were visualised using a minimum spanning tree (MST).

Finally, the minimum inhibitory concentrations (MIC) of 21 antimicrobials were determined for the 328 isolates.

Results and Discussion

Serotype

Only 215 (65%) out of the 328 strains could be serotyped (Table 3). This surprisingly low percentage is partially due to the nonagglutinability of 33 out of 43 CF isolates. Additionally, we suspect that the commercially available monoclonal antibody suspensions are not as potent as some of the homemade antisera that were used in past studies. Eleven strains, including 5 CF isolates, were polyagglutinable. Nonagglutinable strains have lost most or all of their lipopolysaccharide (LPS) and polyagglutinable strains have lost part or all of their O-repeating saccharide units, which determine serotype specificity, due to a defective LPS side chain synthesis [87,88]. Cross-reactions in agglutination are due to core LPS epitopes, which are conserved in all the serotypes. Loss of O serotype reaction was described as one of the distinctive features for *P. aeruginosa* strains isolated from CF patients with chronic bronchopulmonary infection [89]. Already in 1975 Zierdt and Williams reported that isolates from CF patients were frequently polyagglutinable [90]. The predominant serotypes in our collection were O11 (20.1%), O6 (14.2%), O1 (11.9%) and O12 (7.9%) (Table 3). This is in congruence with the findings of Bert and Lambert-Zechowsky, who determined the O-serotypes of 2952 *P. aeruginosa* isolates and found serotypes O11, O6 and O1 to be predominant [91]. The incidence of O12, however, was low. The higher prevalence of serotype O12 in our collection is due to an overrepresentation of MDR strains. As could be expected, most MDR clinical isolates exhibited serotypes O11 and O12 (Figure 1, Figure 2, Figure 3, Figure 4, and Table 3). Finally, we would like to stress that the occasional clustering of isolates with different serotypes is not necessarily the result of recombinational events. It was demonstrated that anti-pseudomonal drugs [92] and bacteriophages [93] were able to induce serotype conversion in *P. aeruginosa*.

FAFLP

The FAFLP patterns of the *P. aeruginosa* strains were normalised and clustered using the Unweighted Pair Group Method with Arithmetic mean (UPGMA). By applying the criteria for differentiation of *P. aeruginosa* by FAFLP [94], which were based on the criteria for pulsed-field gel electrophoresis [95], 44 clusters of related isolates (with $\geq 80\%$ homology) were identified and numbered (Figure 1, Figure 2, Figure 3, Figure 4, and Figure S1). The close genetic relationship between some isolates, illustrated by an almost identical data set (Figure 1, Figure 2, Figure 3, Figure 4), also resulted in very similar FAFLP patterns (Figure S1). This shows that FAFLP can be used, in clinical settings for example, to recognize epidemic *P. aeruginosa* clones during short time spans. In

contrast, the relationship between the different clonal complexes, and sometimes even between distinct clones within a complex, was not always supported by FAFLP (Figure 1, Figure 2, Figure 3, Figure 4). This is illustrated by a congruence of only 54% (lineair correlation) between the similarity matrix of FAFLP and the matrix derived from a combination of all the methods (Figure 5). FAFLP is useful to discriminate between isolates, when investigating local epidemics, but on its own it is not capable to identify clonal complexes and elucidate the population structure of *P. aeruginosa*.

ExoS and exoU

Seventy-three percent of all isolates harboured the *exoS* gene and 23% the *exoU* gene (Table 3). With the exception of three strains, the carriage of *exoU* and *exoS* was mutually exclusive and in 10 isolates neither of the genes could be amplified by PCR (Table 3). Interestingly, 42 of the 43 CF isolates exhibited the *exoS*⁺/*exoU* genotype (Table 3). This could mean that the presence of *exoS*, which is indicative of an invasive phenotype [96], and/or the absence of *exoU*, which has been associated with virulence [83–84] and severity of disease [97], is mandatory for successful colonisation of the CF lung. These results are in congruence with earlier reports. Feltman and colleagues observed that 72% of *P. aeruginosa* isolates contained the *exoS* gene and 28% the *exoU* gene [98]. The presence of the *exoS* and *exoU* genes appeared to be mutually exclusive and they also observed that CF isolates harboured more frequently the *exoS* gene and less frequently the *exoU* gene than did isolates from other sites of infection, including the respiratory tract of patients without CF. Wareham and Curtis also observed an association of the *exoS*⁺/*exoU*⁻ genotype with chronic infection in CF patients, whilst the *exoS*⁻/*exoU*⁺ genotype was associated with strains isolated from blood [99]. The mutual exclusion of *exoS* or *exoU* indicates that selective pressures contributed to the evolution of these genomes in different environmental niches [17]. Because the type III secretion system secretes both ExoS and ExoU, the adaptation to either one of these exoenzymes almost certainly involved interaction with different target eukaryotic organisms. Accordingly, Ferguson *et al.* suggested that in the transition of *P. aeruginosa* from the soil to certain clinical settings, the loss of ExoS expression is favoured [100]. In clinical settings the inactivation of host cell function [101] and the antiphagocytic properties [102] of ExoS should aid in the infectious process, but its limited cytotoxicity, combined with its inefficient targeting of cells of lymphoid origin, may favour the production of more cytotoxic factors, such as ExoU and exotoxin A [103], at certain sites of *P. aeruginosa* infection.

Kulasekara *et al.* suggested that the evolutionary history of the *exoU* locus more than likely involved transposition of the ExoU determinant onto a transmissible plasmid, followed by transfer of this plasmid into different *P. aeruginosa* strains [104]. This is in accordance with our results and would explain the three strains that harbour both *exoS* and *exoU*. The acquisition of novel genetic material, such as the *exoU* genomic island, through HGT, may enhance colonisation and survival in different host environments [17].

OprI, oprL, and oprD

The *oprI*, *oprL*, and *oprD* sequences of the 328 studied *P. aeruginosa* strains were aligned and clustered using UPGMA. Allele codes were arbitrarily assigned and consisted of a capital letter for the allele group and a number, according to their position in the alignment (Figure 6). The *oprI* and *oprL* genes showed moderate sequence variability comparable to that of housekeeping genes, as could be expected since both genes code for a structural outer membrane lipoprotein (Table 4). The *oprI*, *oprL* and *oprD* sequences

Table 3. Differential prevalence (%) of strain characteristics.

Experiment	Type/group	CF	Clinical non-CF	Animal	Environ-mental	Total*	O11	O12 clone	pre 1980
	Number of strains	43	142	63	55	303	61	20	49
Serotype	O1	5 (11.6)	8 (5.6)	11 (17.5)	12 (21.8)	36 (11.9)	0 (0)	0 (0)	5 (10.2)
	O6	4 (9.3)	15 (10.6)	15 (23.8)	9 (16.4)	43 (14.2)	0 (0)	0 (0)	11 (22.4)
	O11	0 (0)	38 (26.8)	11 (17.5)	12 (21.8)	61 (20.1)	61 (100)	0 (0)	3 (6.1)
	O12	0 (0)	23 (16.2)	0 (0)	1 (1.8)	24 (7.9)	0 (0)	20 (100)	0 (0)
	NT	28 (65.1)	39 (27.5)	18 (28.6)	13 (23.6)	98 (32.3)	0 (0)	0 (0)	16 (32.7)
	PA	5 (11.6)	3 (2.1)	0 (0)	1 (1.8)	9 (3.0)	0 (0)	0 (0)	2 (4.1)
	other	1 (2.3)	16 (11.3)	8 (12.7)	7 (12.7)	32 (10.6)	0 (0)	0 (0)	12 (24.5)
<i>exoS/U</i>	S	42 (97.7)	98 (69.0)	46 (73.0)	34 (61.8)	220 (72.6)	13 (21.3)	20 (100)	41 (83.7)
	U	1 (2.3)	36 (25.4)	15 (23.8)	18 (32.7)	70 (23.1)	45 (73.8)	0 (0)	2 (4.1)
	S+U	0 (0)	3 (2.1)	0 (0)	0 (0)	3 (1.0)	1 (1.6)	0 (0)	0 (0)
	NA	0 (0)	5 (3.5)	2 (1.6)	3 (5.5)	10 (3.3)	2 (3.3)	0 (0)	6 (12.2)
<i>oprD</i>	A	1 (2.3)	41 (28.9)	2 (1.6)	15 (27.3)	59 (19.5)	13 (21.3)	20 (100)	10 (20.4)
	B	40 (93.0)	47 (33.1)	29 (46.0)	25 (45.5)	141 (46.5)	3 (4.9)	0 (0)	27 (55.1)
	C	2 (4.7)	53 (37.3)	32 (50.8)	14 (25.5)	101 (33.3)	44 (72.1)	0 (0)	12 (24.5)
	NA	0 (0)	1 (0.7)	0 (0)	1 (1.8)	2 (0.7)	1 (1.6)	0 (0)	0 (0)
	DOM	7 (16.3)	15 (10.6)	0 (0)	0 (0)	22 (7.3)	9 (14.8)	4 (20.0)	0 (0)
<i>oprL</i>	A	1 (2.3)	16 (11.3)	10 (15.9)	12 (21.8)	39 (12.9)	15 (24.6)	0 (0)	4 (8.2)
	B	42 (97.7)	119 (83.8)	46 (73.0)	37 (67.3)	244 (80.5)	43 (70.5)	20 (100)	40 (81.6)
	other	0 (0)	7 (4.9)	7 (11.1)	6 (10.9)	20 (6.6)	3 (4.9)	0 (0)	5 (10.2)
<i>oprI</i>	A	8 (18.6)	23 (16.2)	18 (28.6)	2 (3.6)	51 (16.8)	3 (4.9)	0 (0)	13 (26.3)
	B	35 (81.4)	113 (79.6)	45 (71.4)	52 (94.5)	245 (80.9)	57 (93.4)	20 (100)	33 (67.3)
	other	0 (0)	6 (4.2)	0 (0)	1 (1.8)	7 (2.3)	1 (1.6)	0 (0)	3 (6.1)
<i>fpvA</i>	I	11 (25.6)	38 (26.8)	26 (41.3)	29 (52.7)	104 (34.3)	18 (29.5)	0 (0)	18 (36.7)
	IIa	5 (11.6)	23 (16.2)	12 (19.0)	8 (14.5)	48 (15.8)	10 (16.4)	0 (0)	8 (16.3)
	IIb	20 (46.5)	43 (30.3)	18 (28.6)	13 (23.6)	94 (31.0)	22 (36.1)	0 (0)	5 (10.2)
	III	7 (16.3)	38 (26.8)	7 (11.1)	5 (9.1)	57 (18.8)	11 (18.0)	20 (100)	8 (16.3)
<i>fpvB</i>	POS	43 (100)	131 (92.3)	57 (90.5)	48 (87.3)	279 (92.1)	57 (93.4)	20 (100)	41 (83.7)
	NA	0 (0)	11 (7.7)	6 (9.5)	7 (12.7)	24 (7.9)	4 (6.6)	0 (0)	8 (16.3)
<i>tfpO</i>	a	0 (0)	0 (0)	0 (0)	2 (3.6)	2 (0.7)	0 (0)	0 (0)	1 (2.0)
	b	24 (55.8)	70 (49.3)	26 (41.3)	24 (43.6)	144 (47.5)	10 (16.4)	19 (95.0)	27 (55.1)
	NA	19 (44.2)	72 (50.7)	37 (58.7)	29 (52.7)	157 (51.8)	51 (83.6)	1 (5.0)	21 (42.9)

CF, cystic fibrosis; DOM, defective *oprD* mutation; NA, no amplification; NT, not typable; PA, polyagglutinable; POS, positive.

*Strains of unknown origin (n = 12) and strains isolated from the hospital environment (n = 13) were not considered.

doi:10.1371/journal.pone.0007740.t003

of strains LMG 5031, Br680, CPHL 11451 and PA7 diverged considerably (Figure 6). With the exception of one isolate, all mutations in *oprI* and *oprL* were silent (http://www.pseudomonas.com/related_links.jsp#alleles). All CF isolates but one possessed the group B *oprL* allele (Figure 1, Figure 2, Figure 3, Figure 4, and Table 3). Since non-silent mutations are extremely rare in *oprL*, the conservation of distinct alleles within a clonal complex or clone is likely the result of a genetic linkage or co-selection.

The *oprD* gene showed the expected high sequence variability (Figure 6C and Table 4), typical for a gene that is under strong selection for diversity (http://www.pseudomonas.com/related_links.jsp#alleles). The *oprD* genes of strains US376 and W15 Oct 31 could not be amplified by PCR. The *oprD* gene of these strains is probably not present or exhibits an aberrant nucleotide sequence (at least at the primer annealing sites). With the exception of three isolates (Li004, 5BR2 and MC086), all CF isolates exhibited a group B *oprD* allele (Figure 1, Figure 2,

Figure 3, Figure 4, and Table 3). Although genetic linkage or co-selection between group B *oprD* alleles and parameters that have a significant impact on selection in the CF lung are likely, the important intergroup amino acid differences, especially in the external loops of the OprD porin [74], could be indicative of a more decisive role for OprD in the selection for strains in the CF niche. The actual weight of OprD as a selection force in the CF niche cannot be determined from our data and needs further investigation. Twenty-one different defective *oprD* mutations (DOMs), conferring resistance to carbapenem antibiotics, were observed (Table 3 and Table 5). Seven (16.3%) of the 43 CF isolates exhibited a DOM and as a consequence are expected to express no OprD porin. This could mean that if OprD is truly a selective force in the CF niche, it is likely that it will only be of importance in the early stages of colonisation. Additionally, this relatively high percentage of DOMs suggests that carbapenems have an impact on *P. aeruginosa* in the CF lung. Finally, from the

CC (MST)	Position in Figure S2 (UPGMA)	Strain	Location	Country	Year	Source	Sero-type	FAFLP	<i>oprL</i>	<i>oprD</i>	<i>exoSU</i>	<i>fpvA</i>	<i>fpvB</i>	Tjfo	ABR*
	1	Br262	Brussels	Belgium	1997	Tan water room BWC	11	35	B1 B02	C202	<i>exoS</i>	II a	POS	NA	1
	2	Us411	San Antonio	USA	1991	Urine	11	28	B1 B02	B106	<i>exoS</i>	II a	POS	NA	1
H	3	PER08	Ghent	Belgium	1992	Wound	11	32	B1 B12	C202	<i>exoS</i>	I	POS	NA	3
H	4	IC6	Unknown	India	Unknown	Dog	11	25	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
H	5	CPHL 11450	Kentucky	USA	1982	Unknown	11		B1 B12	A112	<i>exoS</i>	I	POS	Tjfo	1
H	6	CND03	Tbilisi	Georgian Republic	Unknown	Wound	11		B1 B02	B107	<i>exoS</i>	I	POS	Tjfo	2
I	7	Us449	San Antonio	USA	1993	Sputum	11		B1 B04	C110	<i>exoS</i>	III	POS	Tjfo	1
I	8	PER11	Ghent	Belgium	1998	Urine	NT	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
I	9	IC1	Unknown	India	Unknown	Dog	11	40	A1 B04	C208	<i>exoS</i>	III	POS	NA	2
I	10	IC10	Unknown	India	Unknown	Dog	11	40	A1 B04	C208	<i>exoS</i>	III	POS	NA	1
I	11	A9	Paris	France	1882-1918	Surgical bandage	11	31	D1 D01	A115	<i>exoS</i>	III	NA	NA	1
	12	Bu002	Budapest	Hungary	1997	Wound	11	24	B1 B12	B107	<i>exoS</i>	II b	POS	Tjfo	4
	13	AGS3389	Athens	Greece	1994	Sputum	11		B1 B12	C210	<i>exoS</i>	II b	POS	Tjfo	2
	14	Br763	Brussels	Belgium	1998	Tap water operating	11		B1 B02	C202	<i>exoS</i>	II b	POS	NA	1
	15	Us376	San Antonio	USA	1988	Wound	11		B1 B02	NA	<i>exoS</i>	II b**	NA	NA	2
	16	9AR3	De Haan	Belgium	1993	CF-patient	NT		B1 B07	B110	<i>exoS</i>	III	POS	Tjfo	2
	17	LIAR6/2007	Lisbon	Portugal	2007	Dog uterus	NT	7	B1 B12	C106	<i>exoS</i>	III	POS	NA	1
	18	PHLS08959	Liverpool	UK	2003	CF-patient	NT	20	B1 B02	B108	<i>exoS</i>	III	POS	Tjfo	3
	19	LI A122/2005	Lisbon	Portugal	2005	Dog ear	NT	20	B1 B12	B101	<i>exoS</i>	III	POS	Tjfo	1
	20	MC161	Leuven	Belgium	2003	CF-patient	NT	20	B1 B12	B101	<i>exoS</i>	III	POS	Tjfo	TRM
	21	PHLS08916	Birmingham	UK	2003	CF-patient	NT	20	B1 B12	B107	<i>exoS</i>	III	POS	Tjfo	4
	22	13BR3	De Haan	Belgium	1993	CF-patient	NT		A1 B02	B115	<i>exoS</i>	III	POS	NA	2
	23	Li010	Lisbon	Portugal	1997	CF-patient	NT		B1 A07	B104 (DOM6)	<i>exoS</i>	III	POS	Tjfo	5
	24	LMG 14085	Unknown	Hungary	1958-65	Unknown	15		A1 B02	B107	<i>exoS</i>	III	POS	NA	0
	25	CPHL 12447	Chengdu	China	1963	Unknown	18		B1 B12	C106	<i>exoS</i>	III	POS	NA	1
	26	So095	Sofia	Bulgaria	1997	Burn	NT		B1 B12	C106	<i>exoS</i>	III	POS	NA	0
I	27	IC2	Unknown	India	Unknown	Dog	NT	40	A1 B04	C208	<i>exoS</i>	III	POS	NA	2
	28	Bo546	Boston	USA	1992	Burn	12		E1 B15	B114	<i>exoS</i>	I	POS	NA	3
	29	W15 Dec 3	Woluwe river	Belgium	2001	River water	12	28	B1 B12	B101	<i>exoS</i>	I	POS	Tjfo	1
	30	Co399645	Cali	Colombia	2003	Peritoneal fluid	12		A1 B11	C103	<i>exoS</i>	I	POS	Tjfo	0
	31	O12-20	Roehampton	UK	1987	Clinical non CF	12		A1 B11	C103	<i>exoS</i>	I	POS	Tjfo	1
O12	32	Pa6	Brussels	Belgium	1985	Urine	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	3
O12	33	O12-4	Nantes	France	1988	Clinical non CF	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	1
O12	34	So098	Sofia	Bulgaria	1997	Wound	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	35	O12-17	Pordenone	Italy	1988	Clinical non CF	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	3
O12	36	Co7388	Cali	Colombia	1999	Urine	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	3
O12	37	Co380791	Cali	Colombia	2003	Blood	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	38	280381	Geel	Belgium	2004	Clinical non CF	12	37	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	IG
O12	39	PN586(35)w	Panama City	Panama	2006	Catheter	12	37	B1 B08	A111	<i>exoS</i>	III	POS	NA	4
O12	40	1709-12	Leuven	Belgium	2004	Clinical non CF	12	37	B1 B08	A111 (DOM20)	<i>exoS</i>	III	POS	Tjfo	5
O12	41	1709-20	Leuven	Belgium	2004	Clinical non CF	12	37	B1 B08	A111 (DOM20)	<i>exoS</i>	III	POS	Tjfo	5
O12	42	ESP06B	Brussels	Belgium	1993	Clinical non CF	12	38	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	3
O12	43	SIS3740	Athens	Greece	1994	Sputum	12	38	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	44	PER05	Ghent	Belgium	1999	Sputum	12	38	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	2
O12	45	Co398373	Cali	Colombia	2003	Hospital environment	12		B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	3
O12	46	Br667	Brussels	Belgium	1998	Burn	12	33	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	47	Br993	Brussels	Belgium	1999	Sputum	12	33	B1 B08	A111 (DOM13)	<i>exoS</i>	III	POS	Tjfo	5
O12	48	Lo049	London	UK	1996	Burn	12	33	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	49	Br229	Brussels	Belgium	1997	Hospital environment	12	33	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
O12	50	KAT3529	Athens	Greece	1994	Wound	12	39	B1 B08	A111 (DOM16)	<i>exoS</i>	III	POS	Tjfo	4
O12	51	Is586(13T)	Istanbul	Turkey	1997	Burn	12	39	B1 B08	A111	<i>exoS</i>	III	POS	Tjfo	4
	52	Tu863	Tunis	Tunisia	1998	Ear	13		B1 D01	A115	<i>exoS</i>	III	NA	NA	1
	53	PN2140(93)	Panama City	Panama	2006	Catheter	NT	20	B1 B12	C106	<i>exoS</i>	III	NA	NA	1
	54	Us447	San Antonio	USA	1993	Urine	4		B1 B08	A111	<i>exoS+T</i>	III	POS	Tjfo	2
	55	Us451	San Antonio	USA	1993	Burn	4		B1 A06	A114	<i>exoS+T</i>	III	POS	Tjfo	1
	56	MC110	Brussels	Belgium	2003	CF-patient	NT	20	A1 B02	B101	<i>exoS</i>	I	POS	Tjfo	2
	57	MC278	Brussels	Belgium	2003	CF-patient	NT	20	A1 B10	B101	<i>exoS</i>	I	POS	Tjfo	2
	58	CPHL 10701	Surrey	UK	1967	Sputum	NT	20	A1 B07	B107	<i>exoS</i>	I	POS	Tjfo	1
	59	MC361 (blue)	Brussels	Belgium	2003	CF-patient	NT	20	B1 B05	B112	<i>exoS</i>	I	POS	Tjfo	2
	60	MC116	Brussels	Belgium	2003	CF-patient	NT	31	B1 B12	B107 (DOM17)	<i>exoS</i>	I	POS	Tjfo	2
	61	MC305	Ghent	Belgium	2003	CF-patient	NT	31	A1 B02	B101	<i>exoS</i>	I	POS	Tjfo	1
	62	Clone M	Hanover	Germany	1994	CF-patient	NT	20	B1 B12	B106 (DOM15)	<i>exoS</i>	I	POS	Tjfo	1
	63	IDEXXCanine12	Unknown (IDEXX)	UK	2004	Dog	4	20	B1 B14	B107	<i>exoS</i>	I	POS	Tjfo	1
K	64	CPHL 8506	Unknown (NIMR)	UK	1950	Unknown	9	23	B1 B05	B112	<i>exoS</i>	I	POS	Tjfo	1
K	65	LI A11/2004	Almada	Portugal	2004	Cat nose	9	36	A1 B02	B101	<i>exoS</i>	I	POS	Tjfo	2
K	66	CPHL 2000	London	UK	1923	Wound	9	30	A1 B05	B113	<i>exoS</i>	I	POS	Tjfo	0
H	67	IC5	Unknown	India	Unknown	Dog	NT	25	A1 B11	C103	<i>exoS</i>	I	POS	NA	2
H	68	IC7	Unknown	India	Unknown	Dog	NT	25	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
H	69	IC8	Unknown	India	Unknown	Dog	NT	25	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
	70	CPHL 1999	London	UK	1924	Ear	NT	30	A1 B11	C103	<i>exoS</i>	I	POS	NA	0
	71	IC12	Unknown	India	Unknown	Dog	NT	20	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
	72	IDEXXCanine11	Unknown (IDEXX)	UK	2004	Dog	NT	20	A1 B12	C106	<i>exoS</i>	I	POS	NA	1
	73	TA21	Hobart	Australia	2004	Sputum	NT	20	A1 B02	C108	<i>exoS</i>	I	POS	NA	2
	74	PN1352(65)w	Panama City	Panama	2006	Nose	NT	20	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
	75	NCF013	Hobart	Australia	2003	Lung carcinoma	NT	20	A1 B11	C103	<i>exoS</i>	I	POS	NA	1
	76	NCF015	Hobart	Australia	2003	COPD	NT	20	A1 B12	C106	<i>exoS</i>	I	POS	NA	1
	77	TA28	Hobart	Australia	2004	Wound	NT	20	B1 B12	C109	<i>exoS</i>	I	POS	NA	2
	78	TA160	Derwent river tributary	Australia	2005	River water	NT	20	B1 B12	C206	<i>exoS</i>	I	POS	NA	1
	79	MC178 (LCV)	Brussels	Belgium	2003	CF-patient	NT	34	A1 B11	B107	<i>exoS</i>	I	POS	NA	1
	80	MC178 (SCV)	Brussels	Belgium	2003	CF-patient	NT	34	A1 B11	B107	<i>exoS</i>	I	POS	NA	TRM
D	81	J9UH1 F	Jekyll Island	USA	2004	Turtle egg (interior)	1	21	B1 B12	B101	<i>exoS</i>	I	POS	Tjfo	1
D	82	Jp1518	Anakawa river	Japan	2003	River water	1	21	B1 B12	B101	<i>exoS</i>	I	POS	Tjfo	1

Figure 1. Overview of the characteristics and test results of *P. aeruginosa* strains 1-82/328. ABR: antibiotic resistance; ATCC: American Type Culture Collection; BWC: burn wound centre; CC: clonal complex; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CPHL: Central Public Health Laboratory, London; DOM: defective *oprD* mutation; ESP: Ecole de Santé Publique, Brussels; FAFLP: fluorescent amplified fragment length polymorphism; HPA: Health protection Agency, Colindale; HSV: high sequence variability; IDEXX: laboratory for veterinary, food and water testing; ICU: intensive care unit; IG: insufficient growth; LMG: Laboratorium voor Microbiologie Gent, public bacteria collection; NA: no amplification; NIMR: National Institute for Medical Research, London; NT: not typable; POS: positive; TRM: reaction terminated. * ABR: antibiotic resistance, expressed as the number of antibiotic classes to which resistance was observed. ** Detected using degenerate primers.
doi:10.1371/journal.pone.0007740.g001

CC (MST)	Position in Figure S2 (UPGMA)	Strain	Location	Country	Year	Source	Sero-type	FAFLP	oprI	oprL	oprD	exoS/U	fpvA	fpvB	TfpO	ABR*
D	83	LiA63/2006	Lisbon	Portugal	2006	Kangaroo blood	1	21	B1	B12	B101	exoS	I	POS	TfpO ₁	1
D	84	J130UH1 OS5	Jekyll Island	USA	2006	Turtle egg (exterior)	1	21	B1	B17	B107	exoS	I	POS	TfpO ₁	1
D	85	Jp54	Suruga Bay (N2, 200m)	Japan	2004	Sea water (coastal)	1	21	B1	B12	B101	exoS	I	POS	TfpO ₁	1
D	86	Jp60	Suruga Bay (N2, 200m)	Japan	2004	Sea water (coastal)	1	21	B1	B12	B101	exoS	I	POS	TfpO ₁	1
D	87	Jp238	Pacific Ocean (S2, 0m)	Japan	2004	Sea water (coastal)	1	21	A1	B02	B101	exoS	I	POS	TfpO ₁	1
D	88	CNS573	Tbilisi	Georgian Republic	1975	Pleural fluid	1	21	B1	B09	A103	exoS	I	POS	NA	1
D	89	IDEXXCanine1	Unknown (IDEXX)	UK	2004	Dog	1	21	B1	B02	B113	exoS	I	POS	NA	1
D	90	Pr335	Prague	Czech Republic	1997	Hospital environment	1	28	A1	B02	B101	exoS	I	POS	TfpO ₁	1
D	91	A10	Paris	France	1882-1918	Wound	1	28	B1	B12	B103	exoS	I	POS	TfpO ₁	0
D	92	10BR1	De Haan	Belgium	1993	CF-patient	1	14	B1	B12	B107	exoS	I	POS	NA	2
D	93	CPHL 9433	Unknown	The Philippines	1925	Tobacco plant	1	1	B1	A04	A108	exoS	I	POS	TfpO ₁	0
A	94	LiA193/2007	Lisbon	Portugal	2007	Dog ear	1	20	B1	B12	C106	exoS	III	POS	TfpO ₁	1
A	95	Jp235	Sagami Bay	Japan	2003	Sea water (coastal)	NT	27	B1	B12	B107	exoS	I	POS	TfpO ₁	1
A	96	Jp1540	Zenpukujii pond	Japan	2003	Pond water	NT	1	B1	B12	C111	exoS	I	POS	TfpO ₁	1
A	97	IDEXXCanine7	Unknown (IDEXX)	UK	2004	Dog	NT	14	B1	B12	B109	exoS	I	POS	NA	1
A	98	PN119w	Panama City	Panama	2006	Clinical non CF	NT	1	E1	B14	B107	exoS	I	POS	TfpO ₁	1
A	99	Aa249	Aachen	Germany	1997	Burn	NT	30	B1	B12	B107 (DOM7)	exoS	I	POS	TfpO ₁	3
A	100	Bu004	Budapest	Hungary	1997	Throat	NT	32	A1	B12	C106	exoS	I	POS	NA	1
A	101	Bo548	Boston	USA	1992	Burn	NT	1	A1	B12	C107 (DOM12)	exoS	I	POS	NA	2
A	102	So099	Sofia	Bulgaria	1997	Burn	NT	1	A1	B01	C104	exoS	I	POS	NA	4
A	103	IC3	Unknown	India	Unknown	Dog	NT	1	B1	B12	A111	exoS	I	POS	NA	1
A	104	NCF017	Hobart	Australia	2003	Sputum	NT	43	B1	B12	C103	exoS	I	POS	TfpO ₁	1
A	105	CPHL 8058	California	USA	1949	Unknown	NT	41	A1	B11	C103	exoS	I	POS	NA	1
A	106	CPHL 8060	California	USA	1949	Unknown	NT	41	A1	B11	C103	exoS	I	POS	NA	0
A	107	PAO1	Melbourne	Australia	1955	Wound	5	30	A1	B11	C103	exoS	I	POS	NA	1
A	108	W15 Dec 4	Woluwe river	Belgium	2002	River water	5	20	B1	B12	C106	exoS	III	POS	TfpO ₁	1
A	109	Is579	Istanbul	Turkey	1997	Burn	8	30	B1	B02	B112	exoS	IIa**	POS	NA	3
A	110	Br908	Brussels	Belgium	1999	Throat	8	30	B1	B16	C106	exoS	III	POS	NA	1
A	111	CPHL 6750	Elstree	UK	1944	Urine	8	30	B1	B12	C103	exoS	I	POS	TfpO ₁	2
A	112	W5 Aug 16	Woluwe river	Belgium	2002	River water	NT	1	B1	B12	C105	exoS	I	POS	TfpO ₁	1
A	113	PHLS08960	Manchester	UK	2003	CF-patient	NT	7	A1	B02	B107 (DOM14)	exoS	IIb	POS	TfpO ₁	4
A	114	Jp1504	Arakawa river	Japan	2003	River water	NT	7	A1	B12	B101	exoS	IIb	POS	TfpO ₁	1
A	115	M-72	Bucarest	Romania	1965-1978	Faeces	NT	7	A1	B02	B107	exoS	IIb	POS	NA	1
A	116	Lo050	London	UK	1996	Burn	NT	1	B1	B02	B105	exoS	IIb	POS	TfpO ₁	1
A	117	Jp1303	Pacific Ocean (S4, 0m)	Japan	2003	Sea water (open ocean)	NT	1	B1	B02	B101	exoS	IIb	POS	TfpO ₁	0
A	118	CPHL 5083	London	UK	1937	Urine	NT	20	B1	B07	C109	exoS	IIb	POS	NA	0
A	119	Jp1563	Lake Tamako	Japan	2003	Lake water	NT	20	B1	B12	C109	exoS	IIb	POS	NA	1
A	120	LiA124/2005	Lisbon	Portugal	2005	Dog ear	NT	20	A1	B12	C212	exoS	IIb	POS	TfpO ₁	2
A	121	TA03	Hobart	Australia	2004	Wound	NT	20	B1	B02	A113	exoS	IIb	POS	NA	1
A	122	NCF002	Hobart	Australia	2003	Ear	NT	20	B1	B12	A111	exoS	IIb	POS	TfpO ₁	1
A	123	LiA161/2005	Lisbon	Portugal	2005	Parrot eye	NT	20	B1	B07	B107	exoS	IIb	POS	TfpO ₁	2
A	124	LiA6/2006	Lisbon	Portugal	2006	Dog ear	NT	1	B1	B12	B107	exoS	IIb	POS	NA	2
A	125	TA34	Hobart	Australia	2004	Urine	NT	22	A1	B07	B107	exoS	IIb	POS	NA	2
A	126	A11	Paris	France	1882-1918	Wound	NT	28	B1	B12	B101	exoS	IIb	POS	TfpO ₁	0
A	127	A16	Paris	France	1882-1918	Wound	NT	28	B1	B12	B101	exoS	IIb	POS	TfpO ₁	0
A	128	A13	Paris	France	1882-1918	Wound	NT	28	B1	B12	B101	exoS	IIb	POS	TfpO ₁	0
A	129	A20	Paris	France	1882-1918	Wound	NT	28	B1	B12	B101	exoS	IIb	POS	TfpO ₁	0
A	130	Lw1047	Lwiro	Congo	2001	Blood	NT	30	A1	B02	B107	exoS	IIb	POS	TfpO ₁	4
A	131	MC084	Antwerp	Belgium	2003	CF-patient	NT	20	B1	B02	B106	exoS	IIb	POS	NA	1
A	132	MC039	Ghent	Belgium	2003	CF-patient	NT	20	B1	B12	B107 (DOM18)	exoS	IIb	POS	NA	5
A	133	MC093	Leuven	Belgium	2003	CF-patient	NT	21	B1	B02	B106	exoS	IIb	POS	NA	2
A	134	MC325	Ghent	Belgium	2003	CF-patient	NT	21	B1	B02	B106 (DOM19)	exoS	IIb	POS	NA	4
A	135	MC075	Antwerp	Belgium	2003	CF-patient	NT	21	B1	B02	B106	exoS	IIb	POS	TfpO ₁	1
A	136	MC142	Brussels	Belgium	2003	CF-patient	NT	20	B1	B01	B110	exoS	IIb	POS	TfpO ₁	3
A	137	MC099	Ghent	Belgium	2003	CF-patient	NT	20	B1	B02	B101	exoS	IIb	POS	TfpO ₁	3
D	138	MC299	Brussels	Belgium	2003	CF-patient	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	139	TA20	Hobart	Australia	2004	Urine	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	140	SG17M (clone)	Ruhr river	Germany	1992	River water	1	28	B1	B02	B106	exoS	IIb	POS	NA	1
D	141	SG50M (clone)	Mülheim	Germany	1992	Swimming pool water	1	28	B1	B02	B106	exoS	IIb	POS	NA	1
D	142	W5 Aug 28	Woluwe river	Belgium	2002	River water	1	28	B1	B02	B106	exoS	IIb	POS	NA	1
D	143	LiA9/2003	Porto Alto	Portugal	2003	Horse vagina	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	144	LiA10/2003	Porto Alto	Portugal	2003	Horse vagina	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	145	LiA165/2007	Estoril	Portugal	2007	Horse uterus	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	146	C13	Hannover	Germany	1985	CF-patient	1	28	B1	B02	B106	exoS	IIb	POS	NA	0
D	147	U018A (CF type)	Hobart	Australia	2003	CF-patient	1	20	B1	B12	B110	exoS	IIb	POS	TfpO ₁	1
D	148	PN891(95)	Panama City	Panama	2006	Clinical non CF	1	21	B1	B02	B106	exoS	IIb	POS	NA	1
D	149	A12	Paris	France	1882-1918	Wound	1	28	B1	B12	B101	exoS	IIb	POS	TfpO ₁	0
D	150	C (clone C)	Hannover	Germany	1989	CF-patient	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	2
D	151	C1 (clone C)	Hannover	Germany	1987	CF-patient	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	2
D	152	C18 (clone C)	Hannover	Germany	1989	Hospital environment	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	1
D	153	C17 (clone C)	Hannover	Germany	1989	Hospital environment	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	0
D	154	PT31M (clone)	Mülheim	Germany	1986	Drinking water	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	1
D	155	C19 (clone C)	Hannover	Germany	1989	CF-patient	1/13	28	B1	B02	B106 (DOM5)	exoS	IIb	POS	NA	3
D	156	C2 (clone C)	Hannover	Germany	1988	CF-patient	1/13	28	B1	B02	B106	exoS	IIb	POS	NA	2
D	157	U003A (CF type)	Hobart	Australia	2003	CF-patient	1	43	B1	B12	B110	exoS	IIb	POS	TfpO ₁	4
D	158	M-95	Bucarest	Romania	1965-1978	Faeces	1/3	28	B1	B12	B102	exoS	IIb	POS	TfpO ₁	1
D	159	TA08	Hobart	Australia	2003	Sputum	3	20	B1	B12	B107	exoS	IIb	POS	NA	1
D	160	Li012	Lisbon	Portugal	1997	CF-patient	NT	28	B1	B05	B101	exoS	IIb	POS	TfpO ₁	1
D	161	TA06	Hobart	Australia	2004	Urine	NT	1	B1	B14	B107	exoS	IIb	POS	TfpO ₁	4
D	162	PhDW6	Tacloban City	The Philippines	1993	Wound	NT	1	A1	B13	B101	exoS	IIb	POS	TfpO ₁	2
J	163	J66UHS F21	Jekyll Island	USA	2005	Turtle egg (interior)	6	19	B1	C01	B204	exoS	IIa	NA	NA	1
J	164	J130UHS IS6	Jekyll Island	USA	2006	Turtle egg (interior)	6	19	B1	C01	B204	exoS	IIa	NA	NA	1

Figure 2. Overview of the characteristics and test results of *P. aeruginosa* strains 83-164/328. doi:10.1371/journal.pone.0007740.g002

CC (MST)	Position in Figure S2 (UPGMA)	Strain	Location	Country	Year	Source	Sero-type	FAFLP	oprI	oprL	oprD	exoS/U	fpvA	fpvB	TfpO	ABR*
A	165	W15 Oct 31	Woluwe river	Belgium	2002	River water	6	29	B1	B14	NA	exoS	IIa	POS	TfpO ₁	1
A	166	CPHL 10299	Colindale	UK	1962	Faeces	6	22	B1	B02	B110	exoS	IIb	POS	TfpO ₁	1
A	167	LiA116/2006	Santarém	Portugal	2006	Goat brain	6	22	B1	B12	B107	exoS	IIb	POS	NA	1
A	168	Jp1587	Lake Tamako	Japan	2003	Lake water	6	20	B1	B07	B101	exoS	IIb	POS	NA	1
A	169	CPHL 10332	Unknown	Czechoslovakia	1963	Unknown	6	22	B1	B02	B107	exoS	IIb	POS	TfpO ₁	2
A	170	A22	Paris	France	1882-1918	Wound	6	20	B1	B12	B107	exoS	IIb	POS	TfpO ₁	1
A	171	LiA137/2003	Lisbon	Portugal	2003	Dog eye	6	20	B1	B12	B107	exoS	IIb	POS	TfpO ₁	1
A	172	LiA124/2007	Santarém	Portugal	2007	Cow milk	6	20	AI	B12	C212	exoS	IIb	POS	TfpO ₁	1
A	173	Br670	Brussels	Belgium	1998	Sputum	6	30	B1	B07	B107 (DOM8)	exoS	IIb	POS	TfpO ₁	3
A	174	Br776	Brussels	Belgium	1998	Throat	6	20	B1	B12	B110	exoS	IIb	POS	TfpO ₁	4
A	175	Br257	Brussels	Belgium	1997	Plant rhizosphere	6	30	B1	B14	B107	exoS	IIb	POS	TfpO ₁	0
A	176	Lw1048	Lwiro	Congo	2001	Blood	6	20	B1	B12	B110	exoS	IIb	POS	TfpO ₁	4
A	177	LiA50/2005	Alcobaça	Portugal	2005	Dog ear	6	36	AI	B14	B107	exoS	IIb	POS	TfpO ₁	0
A	178	Jp245	Otsuchuki Bay	Japan	2004	Dolphin	6	26	AI	B14	B107	exoS	IIb	POS	TfpO ₁	1
A	179	LiA009	Lisbon	Portugal	1997	CF-patient	6	34	B1	B07	B111	exoS	IIb	POS	NA	0
A	180	LiA228/2006	Lisbon	Portugal	2006	Dog eye	6	34	AI	B07	B107	exoS	IIb	POS	TfpO ₁	1
A	181	ATCC 27853	Boston	USA	1971	Blood	6	30	B1	B14	B107	exoS	IIb	NA	TfpO ₁	0
A	182	LiA70/2004	Santarém	Portugal	2004	Cow milk	6	20	B1	B13	B107	exoS	I	POS	TfpO ₁	1
A	183	LiA83/2005	Santo António	Portugal	2005	Dog ear	6	20	B1	B12	B116	exoS	I	POS	NA	1
A	184	LiA18/2003	Famões	Portugal	2003	Cat vagina	6	20	B1	B12	B107	exoS	I	POS	TfpO ₁	0
A	185	CPHL 6749	Elstree	UK	1944	Urine	6	20	B1	B12	C103	exoS	I	POS	TfpO ₁	1
A	186	CPHL 6751	Elstree	UK	1944	Urine	6	20	B1	B12	C103	exoS	I	POS	TfpO ₁	1
A	187	A17	Paris	France	1882-1918	Leg ulcer	6	20	B1	B12	B107	exoS	I	POS	TfpO ₁	1
A	188	A18	Paris	France	1882-1918	Leg ulcer	6	20	CI	B12	B107	exoS	I	POS	TfpO ₁	1
A	189	M-406	Bucarest	Romania	1965-1978	Bile	6	29	B1	B13	B107	exoS	I	POS	TfpO ₁	1
A	190	MC086	Ghent	Belgium	2003	CF-patient	6	20	B1	B02	C106	exoS	I	POS	TfpO ₁	1
A	191	Clone J	Hanover	Germany	1994	CF-patient	6	26	B1	B12	B107	exoS	I	POS	TfpO ₁	1
A	192	TA05	Hobart	Australia	2003	Sputum	6	26	B1	B12	B107	exoS	I	POS	TfpO ₁	1
A	193	Jp241	Sagami Bay (S1, 0m)	Japan	2004	Sea water (coastal)	6	27	B1	B12	B107	exoS	I	POS	TfpO ₁	1
A	194	LiA145/2005	Lisbon	Portugal	2005	Dog ear	6	7	B1	A02	C105	exoS	I	POS	TfpO ₁	2
A	195	LiA37/2006	Lisbon	Portugal	2006	Dog ear	6	7	B1	A02	C105	exoS	I	POS	TfpO ₁	2
A	196	Mil159	Ann Arbor	USA	1997	Pressure sore	6	30	B1	B02	B101	exoS	III	POS	NA	2
A	197	CPHL 950	Detroit	USA	1921	Unknown	6	30	B1	B12	B110	exoS	III	NA	TfpO ₁	1
A	198	LiA111/2005	Lisbon	Portugal	2005	Dog subcutaneous abscess	6	20	AI	B02	B117	exoS	III	POS	TfpO ₁	1
A	199	59.20	Cambridge	UK	pre 1936	Plant	6	20	B1	B02	B110	exoS	III	POS	TfpO ₁	2
A	200	PN2800(125)	Panama City	Panama	2006	Clinical non CF	6	20	B1	B12	B118	exoS	III	POS	NA	2
A	201	AES1	Australia	Australia	1999	CF-patient	6	20	AI	B02	B119	exoS	III	POS	TfpO ₁	1
A	202	NSWPA15a	North Sea	Belgium	2007	Sea water (coastal)	6	19	B1	B12	B107	exoS	III	POS	TfpO ₁	1
A	203	W11 Aug 25	Woluwe river	Belgium	2002	River water	6	20	B1	B02	B107	exoS	III	NA	TfpO ₁	1
	204	NC014	Hobart	Australia	2003	Lung carcinoma	NT	20	B1	B12	B110	exoS	IIa	POS	TfpO ₁	1
	205	TA151	Hobart	Australia	2005	Swimming pool water	NT	20	B1	B12	A106	exoS	IIa	POS	TfpO ₁	0
J	206	M-184	Bucarest	Romania	1965-1978	Faeces	1/3/10/13	7	AI	B02	B107	exoS	IIa	POS	NA	1
J	207	M-237	Bucarest	Romania	1965-1978	Faeces	3/10/13	7	AI	B02	B107	exoS	IIa	POS	NA	1
J	208	LUH 7552	Holiday camps	The Netherlands	2001	CF-patient	1/3/10/13	7	B1	B02	B106 (DOM15)	exoS	IIb	POS	NA	3
J	209	Is580	Istanbul	Turkey	1997	Burn	3	30	B1	B03	B108	exoS	IIa	POS	NA	4
J	210	A19	Paris	France	1882-1918	Wound	3	20	B1	B12	B107	exoS	IIa	POS	NA	0
J	211	M-280	Bucarest	Romania	1965-1978	Faeces	3	7	AI	B02	B107	exoS	IIa	POS	NA	1
J	212	IDEXXCamine2	Unknown (IDEXX)	UK	2004	Dog	3	20	B1	B03	B108	exoS	IIa	NA	NA	2
J	213	J130UH1 OSS	Jekyll Island	USA	2006	Turtle egg (exterior)	3	20	B1	C01	B204	exoS	IIa	NA	NA	1
J	214	J66UH5 F22	Jekyll Island	USA	2005	Turtle egg (interior)	3	19	B1	C01	B204	exoS	IIa	NA	NA	1
J	215	M-79	Bucarest	Romania	1965-1978	Urine	NT	7	AI	B02	B107	exoS	IIa	POS	TfpO ₁	1
	216	5BR2	De Haan	Belgium	1993	CF-patient	NT	20	B1	B07	C109	exoS	IIa	POS	NA	2
	217	IC11	Unknown	India	Unknown	Dog	NT	20	AI	B12	C103	exoS	IIa	POS	NA	1
	218	C5311 (RAPD)	Vancouver	Canada	2002	CF-patient	NT	20	B1	B13	B107	exoS	IIa	POS	TfpO ₁	3
	219	TA04	Hobart	Australia	2003	Foot ulcer	NT	20	AI	B07	B107	exoS	IIa	POS	TfpO ₁	1
	220	MC096	Leuven	Belgium	2003	CF-patient	NT	20	B1	B12	B106	exoS	IIa	POS	TfpO ₁	0
	221	MC361 (green)	Brussels	Belgium	2003	CF-patient	NT	20	B1	B02	B107	exoS	IIa	POS	NA	1
	222	C3128 (RAPD)	Vancouver	Canada	2002	CF-patient	NT	21	B1	B02	B106	exoS	IIa	POS	NA	2
	223	A237	Paris	France	1882-1918	Rabbit	NT	20	AI	B02	B108	exoS	IIa	POS	TfpO ₁	1
K	224	Us448	San Antonio	USA	1993	Urine	9	30	B1	A03	B107	exoS	IIa	POS	TfpO ₁	1
K	225	TuD47	Tunis	Tunisia	1998	Ascite	9	17	B1	B02	A102	exoS	IIa	POS	TfpO ₁	0
K	226	LiA133/2003	Lisbon	Portugal	2003	Seal organs	9	17	B1	C01	B203	exoS	IIa	NA	TfpO ₁	1
	227	W15 Aug 23	Woluwe river	Belgium	2002	River water	NT	29	B1	B02	B107	exoS	IIa	POS	TfpO ₁	1
	228	CPHL 8203	London	UK	1950	Urine	NT	20	B1	B11	C106	exoS	IIa	NA	NA	0
	229	Br735 (AFLP 8)	Brussels	Belgium	1998	Burn	NT	20	B1	A05	C204	exoS	IIa	POS	NA	1
	230	LMG 14083	Unknown	Hungary	1958-65	Unknown	16	30	B1	B12	C102	exoS	IIb	NA	NA	0
	231	LiA135/2003	Lisbon	Portugal	2003	Dog mucosa	NT	20	B1	B11	C106	exoS	IIb	POS	TfpO ₁	1
	232	Br680	Brussels	Belgium	1998	Burn	12	20	FI	E01	A201	exoS	IIb	NA	TfpO ₁	0
	233	Bu007	Budapest	Hungary	1997	Burn	NT	10	B1	B02	C202 (DOM7)	exoU	IIb	POS	NA	1
	234	TA124	Hobart	Australia	2005	Hospital environment	NT	12	B1	B02	C201	exoU	IIb	POS	NA	3
	235	Li004	Lisbon	Portugal	1997	CF-patient	7	5	B1	B02	A106	exoU	IIb	POS	TfpO ₁	2
	236	M-100	Bucarest	Romania	1965-1978	Unknown	NT	5	B1	B02	A106	exoU	IIb	POS	TfpO ₁	0
F	237	Pr317	Prague	Czech Republic	1996	Burn	11	11	B1	B02	C202 (DOM10)	exoU	IIb	POS	NA	5
F	238	Pr334	Prague	Czech Republic	1997	Hospital environment	11	11	B1	B02	C202 (DOM10)	exoU	IIb	POS	NA	5
F	239	W15 Dec 14	Woluwe river	Belgium	2001	River water	11	12	B1	B02	C202	exoU	IIb	POS	NA	4
F	240	AGO4092	Athens	Greece	1994	Urine	11	12	B1	B02	C202	exoU	IIb	POS	NA	3
F	241	Is582	Istanbul	Turkey	1997	Burn	11	9	B1	B02	C202 (DOM2)	exoU	IIb	POS	NA	5
F	242	So103	Sofia	Bulgaria	1997	Wound	11	9	B1	B02	C202	exoU	IIb	POS	NA	3
F	243	Br692	Brussels	Belgium	1998	Burn	11	10	B1	B02	C202	exoU	IIb	POS	NA	3
F	244	Is573	Istanbul	Turkey	1997	Burn	11	10	B1	B02	C202 (DOM2)	exoU	IIb	POS	TfpO ₁	5
F	245	Aa245	Aachen	Germany	1997	Burn	11	11	B1	B02	C202 (DOM3)	exoU	IIb	POS	NA	5
F	246	So092	Sofia	Bulgaria	1997	Burn	11	11	B1	B02	C201	exoU	IIb	POS	NA	3

Figure 3. Overview of the characteristics and test results of P. aeruginosa strains 165-246/328. doi:10.1371/journal.pone.0007740.g003

CC (MST)	Position in Figure S2 (UPGMA)	Strain	Location	Country	Year	Source	Sero-type	FAFLP	oprI	oprL	oprD	exoS/U	fpvA	fpvB	TfpO	ABR*
F	247	Mi151	Ann Arbor	USA	1997	Bum	11		B1	B02	A106	exoU	II b	POS	TfpO	1
F	248	LiA96/2004	Algarve	Portugal	2004	Dolphin respiratory tract	11	22	B1	B02	C211	exoU	II b	POS	NA	2
F	249	LiA91/2004	Algarve	Portugal	2004	Dolphin skin Lesion	11	22	B1	B02	C211	exoU	II b	POS	NA	1
F	250	LiA86/2004	Porto Alto	Portugal	2004	Horse uterus	11	22	B1	B02	C211	exoU	II b	POS	NA	4
F	251	LiA131/2005	Lisbon	Portugal	2005	Dog skin	11	22	B1	B02	C211	exoU	II b	POS	NA	1
F	252	Mex2	Lofitun	Mexico	2004	Cenote water	11	24	B1	B06	C209	exoU	II b	POS	NA	1
F	253	EVA3067	Athens	Greece	1994	Urine	11		B1	B06	C209	exoU	II b*	POS	NA	1
F	254	Aa246	Aachen	Germany	1997	Bum	11		B1	A07	C203	exoU	II b	POS	NA	1
F	255	Br678	Brussels	Belgium	1998	Bum	11		B1	B02	C202 (DOM13)	exoS+U	II b*	POS	NA	5
F	256	Li767	Lisbon	Portugal	1998	Bum	11	8	B1	A07	C205	exoU	III	POS	NA	2
F	257	Bel34	Beverwijk	The Netherlands	1997	Wound	11	8	B1	A07	C205	exoU	III	POS	NA	1
F	258	Is574	Istanbul	Turkey	1997	Bum	11	8	B1	A07	C205	exoU	III	POS	NA	2
F	259	So123	Sofia	Bulgaria	1997	Hospital environment	11	8	B1	A07	C205	exoU	III	POS	NA	2
F	260	Us500	San Antonio	USA	1996	Sputum	11		B1	A07	C205	exoU	III	POS	NA	1
F	261	Br817	Brussels	Belgium	1998	Wound	11		B1	A07	C205	exoU	III	POS	NA	1
G	262	LiA175/2007	Anadora	Portugal	2007	Turtle shell	11		B1	A07	C203	exoU	II a	POS	NA	3
G	263	PN1296(62)	Panama City	Panama	2006	Wound	11		B1	B02	C202 (DOM21)	exoU	II a	POS	NA	5
G	264	Us450	San Antonio	USA	1993	Bum	11	35	B1	B02	C103	exoU	II a	POS	TfpO	1
G	265	Us365	San Antonio	USA	1986	Wound	11	35	B1	B02	C202	exoU	II a	POS	NA	0
G	266	Bo562	Boston	USA	1997	Blood	11		B1	B06	C209	exoU	II a	POS	NA	1
G	267	Br693	Brussels	Belgium	1998	Wound	11	30	B1	B02	A102	exoU	II a	POS	NA	1
G	268	Br231	Brussels	Belgium	1997	Hospital environment	11		B1	B02	A102	exoU	II a	POS	TfpO	1
G	269	Mi162	Ann Arbor	USA	1997	Bum	11	30	B1	B06	C209 (DOM11)	exoU	II a**	POS	NA	4
G	270	IC4	Unknown	India	Unknown	Dog	11		B1	B02	C202	exoU	II a	POS	NA	2
G	271	Br225	Brussels	Belgium	1997	Hospital environment	11		B1	B06	C202	exoU	II a	POS	TfpO	1
G	272	Br227	Brussels	Belgium	1997	Hospital environment	11		B1	B02	A102	exoU	II a	POS	TfpO	1
F	273	LiA19/2007	Glória do Ribatejo	Portugal	2007	Parrot nose	11	6	B1	B02	C209	exoU	I	POS	NA	2
F	274	LiA118/2007	Glória do Ribatejo	Portugal	2007	Parrot nose	11	6	B1	B02	C209	exoU	I	POS	TfpO	3
F	275	PAO29	Karachi	Pakistan	1998	River water	11	13	B1	B02	C209	exoU	I	POS	NA	1
F	276	PN10732	Panama City	Panama	2005	Wound	11	6	B1	A05	A101	exoU	I	POS	NA	4
F	277	PN2290(117)	Panama City	Panama	2006	Clinical non CF	11		B1	B02	C209	exoU	I	POS	NA	1
F	278	Lo062	London	UK	1996	Wound	11	24	B1	B06	C209	exoU	I	POS	NA	2
F	279	Bel128	Beverwijk	The Netherlands	1997	Sputum	11	2	B1	B02	C209 (DOM1)	exoU	I	POS	NA	1
F	280	Br764	Brussels	Belgium	1998	Tap water operating	11	2	B1	B02	C209	exoU	I	POS	NA	3
F	281	TuD199	Tunis	Tunisia	1998	Sputum	11	1	B1	A05	A101	exoU	I	POS	TfpO	1
F	282	Jp1140	Pacific Ocean (S2, 0m)	Japan	2003	Sea water (coastal)	11	44	B1	A02	A101	exoU	I	POS	NA	1
F	283	Jp1206	Pacific Ocean (S2, 0m)	Japan	2003	Sea water (open ocean)	11	44	B1	A02	A101	exoU	I	POS	TfpO	1
F	284	Jp1170	Pacific Ocean (S2, 0m)	Japan	2003	Sea water (open ocean)	11	44	B1	A02	A101	exoU	I	POS	NA	0
F	285	Jp1200	Pacific Ocean (S2, 0m)	Japan	2003	Sea water (open ocean)	11	44	B1	A02	A101	exoU	I	POS	NA	1
F	286	Jp1155	Pacific Ocean (S2, 0m)	Japan	2003	Sea water (open ocean)	11	44	B1	A02	A101	exoU	I	POS	NA	1
F	287	Jp224	Pacific Ocean (S2, 0m)	Japan	2004	Sea water (open ocean)	11	44	B1	A02	A101	exoU	I	POS	NA	1
	288	Lo053	London	UK	1996	Bum	NT	30	B1	B06	C209	exoU	II a	POS	NA	5
	289	IDEXXCanine6	Unknown (IDEXX)	UK	2004	Dog	NT	22	B1	A02	C202	exoU	II a	POS	NA	1
	290	IDEXXCanine3	Unknown (IDEXX)	UK	2004	Dog	NT	14	B1	A02	A107	exoU	II a	POS	TfpO	2
	291	Bel136	Beverwijk	The Netherlands	1996	Sputum	3		B1	A02	A110	exoU	II a	POS	TfpO	1
	292	Br906	Brussels	Belgium	1999	Nose	6	3	B1	A01	A109	exoU	III	POS	NA	1
	293	Tu61	Mediterranean Sea	Tunisia	2000	Sea water (coastal)	6	3	B1	A01	A109	exoU	III	POS	NA	1
	294	Jp222	Pacific Ocean (S2, 0m)	Japan	2004	Sea water (open ocean)	6	15	B1	B06	A103	exoU	I	POS	TfpO	1
	295	Bel133	Beverwijk	The Netherlands	1996	Bum	NT		B1	A02	A102	exoU	III	POS	NA	0
	296	PAO23	Karachi	Pakistan	1998	River water	NT	13	B1	B02	C209	exoU	I	POS	NA	0
	297	Br641	Brussels	Belgium	1998	Hospital environment	12	1	B1	B08	A101	exoS+U	I	POS	TfpO	1
E	298	PN3529(134)w	Panama City	Panama	2006	Wound	1		B1	B06	A103	exoU	I	POS	TfpO	1
E	299	Cotonu 1	Cotonu	Benin	2008	River water	1	15	B1	B06	A103	exoU	I	POS	TfpO	1
E	300	Br642	Brussels	Belgium	1998	Hospital environment	1	4	B1	B06	A103	exoU	I	POS	TfpO	1
E	301	Ro124	Rotterdam	The Netherlands	1997	Bum	1	4	B1	B06	A103	exoU	I	POS	TfpO	2
E	302	LMG 2107	Canas	Puerto Rico	1938	Shallow well water	1		B1	A05	A104	exoU	I	POS	TfpO	1
E	303	W15 Apr 4	Woluwe river	Belgium	2002	River water	1		B1	B06	A103	exoU	I	POS	TfpO	1
E	304	LiA7/2007	Lisbon	Portugal	2007	Dog eye	1	16	B1	A02	C202	exoU	I	POS	TfpO	1
E	305	LiA141/2007	Lisbon	Portugal	2007	Dog eye	1	16	B1	A02	C202	exoU	I	POS	NA	0
E	306	LiA146/2006	Lisbon	Portugal	2006	Dog pleural fluid	1	16	B1	A02	C202	exoU	I	POS	TfpO	1
E	307	LiA179/2006	Lisbon	Portugal	2006	Dog eye	1	16	B1	A02	C202	exoU	I	POS	TfpO	1
E	308	Bo559	Boston	USA	1997	Bum	1		B1	B06	A103	exoU	I	POS	TfpO	1
	309	UCBPP-PA14	Boston	USA	Unknown	Wound	10	42	B1	A05	C207	exoU	I	POS	NA	1
	310	IDEXXCanine4	Unknown (IDEXX)	UK	2004	Dog	10	42	B1	A05	C207	exoU	I	POS	NA	1
	311	Jp97	Pacific Ocean (N7, 200m)	Japan	2004	Sea water (open ocean)	2	6	B1	A07	C202	exoU	I	POS	NA	1
	312	Jp100	Pacific Ocean (N7, 0m)	Japan	2004	Sea water (open ocean)	2	6	B1	A07	C202	exoU	I	POS	NA	1
J	313	J80UH3 OS1	Jekyll Island	USA	2005	Turtle egg (exterior)	3	18	B1	C01	B203	exoS	II a	NA	NA	1
J	314	J80UH1 OS1	Jekyll Island	USA	2005	Turtle egg (exterior)	3	18	B1	C01	B203	exoS	II a	NA	NA	1
J	315	J66UH5 F7	Jekyll Island	USA	2005	Turtle egg (interior)	3	19	B1	C01	B204	exoS	II a	NA	NA	1
	316	J80UH2 OS2	Jekyll Island	USA	2005	Turtle egg (exterior)	NT	18	B1	C01	B203	exoS	II a	NA	NA	1
	317	CPHL 10662	London	UK	1969	Human	NT		B1	A05	C204	NA	II a	POS	NA	2
I	318	A14	Paris	France	1882-1918	Wound	11	31	B1	D01	A116	NA	III	NA	NA	1
I	319	A15	Paris	France	1882-1918	Wound	11	31	B1	D01	A116	NA	III	NA	NA	1
	320	CPHL 8505	Unknown (NIMR)	UK	1950	Unknown	3		B1	D02	A117	NA	III	POS	TfpO	1
	321	LMG 14084	Bucarest	Romania	1960-64	Water	17		B1	A05	A105	NA	I	POS	NA	1
	322	IDEXXCanine8	Unknown (IDEXX)	UK	2004	Dog	8	23	B1	D03	C101	NA	I	POS	NA	2
	323	DVL1758	Ghent	Belgium	2003	Shallow pond water	NT		B1	C02	B201	NA	I	NA	NA	1
	324	CPHL 11451	Kentucky	USA	1982	Unknown	12		F1	E01	A202	NA	II b	NA	TfpO	0
	325	PA7	Buenos Aires	Argentina	pre 1984	Wound	12		F1	E03	A204	NA	II b	NA	NA	4
	326	LMG 5031	Unknown	Puerto Rico	1961	Chinese evergreen	NT		F1	E02	A203	NA	II b	NA	NA	1
	327	IDEXXCanine5	Unknown (IDEXX)	UK	2004	Dog	6	17	B1	C01	B203	NA	II b	POS	NA	1
	328	TA19	Hobart	Australia	2004	Urine	NT	18	B1	C01	B202	NA	II b	NA	NA	1

Figure 4. Overview of the characteristics and test results of P. aeruginosa strains 247-328/328. doi:10.1371/journal.pone.0007740.g004





Figure 5. Congruence between experiments, as calculated using the Pearson product-moment correlation coefficient.
doi:10.1371/journal.pone.0007740.g005

congruence chart (Figure 5) we learn that the similarity matrix obtained from the *oprD* data alone is almost identical to that obtained from *oprD*, *oprL* and *oprI* combined, indicating that *oprL* and *oprI* add little or nothing to the discriminatory power of *oprD*.

Pyoverdine receptors

No significant correlation could be established between the *fpvA* pyoverdine receptor gene type and habitat (Table 3). De Vos *et al.* reported a prevalence of pyoverdine type II isolates in CF patients and suggested that there might be a correlation between *fpvA* type and the (clinical) origin of the *P. aeruginosa* isolates [105]. We did observe a higher prevalence of pyoverdine type II, and more specifically type IIb (46.5%), in the CF isolates as compared to the total collection (31.0%) (Table 3), but it seems unlikely that the pyoverdine receptor is in itself a selective force in the CF niche.

The relatively unordered distribution of the different pyoverdine receptor types over the different clonal complexes is suggestive for multiple recombinatorial events involving pyoverdine receptors (Figure 1, Figure 2, Figure 3, Figure 4) and a complex evolutionary history. Tümmler and Cornelis reviewed the evolution of the pyoverdine receptor in *P. aeruginosa* and claimed that the pyoverdine region is the most divergent locus of the core genome because it is subject to speciation and coevolution, encodes a trait of altruistic cooperation (the production of siderophores), and encodes a receptor that is both a major fitness allele and a major deleterious allele [79]. Indeed, the mosaic dispersal of *fpvA* types among the different clonal complexes (Figure 1, Figure 2, Figure 3, Figure 4) is possibly the result of the selection pressure caused by bacteriocins, which use the pyoverdine receptors to enter the bacteria. Pyocin S3 was shown to use the type II FpvA receptor, while pyocin S2 was found to kill strains harbouring the type I FpvA receptor [106–107].

As expected, the *fpvB* gene was present in the majority (93.4%) of *P. aeruginosa* isolates, including all 43 CF isolates.

TfpO

The *tfpO* gene, indicative for group I pilins, was detected in 48.2% of isolates (Table 3). The *tfpOa* allele was very rare; it was only detected in four isolates (Table 3). The *tfpO* gene was present in 55.8% of CF isolates, which is only slightly higher than the average (48.2%). Thus, in contrast to Kus *et al.* [86] who detected the *tfpO* gene in 69.7% of CF isolates, we did not find a strong association of *tfpO* with CF. The *tfpO* data were found to have only very limited value and discriminatory power and were therefore not included in the combined analysis.

Population structure

MSTs have long been used in the context of mathematical topology. When a set of distances is given between entries (strains

in this case), a minimum spanning tree connects all entries in such a way that the summed distance of all branches of the tree is the shortest possible [108]. In a biological context, this principle adheres to the idea that evolution should be explained in as few events as possible. MST suffers from a serious degree of degeneracy as it generates a large number of solutions, many of which have no biological relevance. Hence, priority rules are applied in order to find or assign the biologically most relevant solution amongst the many solutions. MST analysis was originally developed to link MLVA-derived sequence types (STs) [109], but technically it can be used for any data type, as long as a true distance matrix can be calculated. The MST principle, however, requires that all samples are present in the data set to construct the tree. Internal branches are normally also based upon existing samples. This means that, when an MST is calculated for evolutionary studies, there are two important conditions that have to be met: (1) the study must focus on a short time-frame, assuming that all forms or states are still present, and (2) the sampled data set must be sufficiently complete to enable the method to construct a valid tree, i.e. representing the full biodiversity of forms or states as closely as possible [108]. A major advantage of the MST approach is that the algorithm may result in trees with star-like branches, which allows for a correct classification of population systems that have a strong mutational or recombinational rate, such as *P. aeruginosa*, and where a large number of single locus variants (SLVs) may evolve from one common type [7]. As mentioned above, MSTs can be calculated from a true distance matrix. A distance matrix based upon a data matrix (in the case of fingerprint type data, derived after a global band matching), whether derived from one or multiple data sources, can be used. In theory, every distance coefficient applied on a data matrix produces a distance matrix suitable for analysis with the MST method [108]. Recently MST was used to determine the phylogenetic framework of *Listeria monocytogenes* [110]. In this study MST was used, for the first time, to link the Polyphasic Profiles (PPs) of 328 unrelated *P. aeruginosa* strains in such a way that the sum of the distances (number of differences between two distinct PPs) is minimized.

In our previous *P. aeruginosa* population structure study a UPGMA dendrogram, based on the comparison of the composite data set consisting of 4 markers in 73 strains, revealed 7 distinct clonal complexes, arbitrarily labelled CC A to CC G [13]. In the present MST, based on the composite similarity matrix derived from the combination of 7 markers in 328 strains (Figure 7), we identified 4 additional clonal complexes (CC H to CC K). The former CC C was renamed ‘clone O12’ to avoid confusion with the worldwide CF and aquatic clone C [3] and the former CC B disappeared as its members no longer clustered into a distinct clonal complex. We also observed several distinct isolates with a unique PP, some of which diverged considerably from the rest of




Figure 6. UPGMA dendrograms, with assignment of allele codes, for the *oprI* (a), *oprL* (b), and *oprD* (c) alleles detected in 328 *P. aeruginosa* strains.

doi:10.1371/journal.pone.0007740.g006

Table 4. Analysis of the *oprI*, *L*, and *D* nucleotide sequence data in 328 *P. aeruginosa* strains.

Gene	Size (bp)	No. of alleles	No. of variable sites	% Variable sites	Max. nucleotide distance between alleles (%)
<i>oprI</i>	249	6	7	2.8	1.5
<i>oprL</i>	504	33	27	5.4	4.0
<i>oprD</i>	1323 or 1329	67	274	20.7	9.5

doi:10.1371/journal.pone.0007740.t004

the population (e.g. reference strains PA7 and UCBPP-PA14). Strains isolated from inanimate environments, animals and humans, separated by thousands of miles, often clustered into the same clonal complex, confirming that, in general, there is no clear correlation between the clonal complexes and geographical origin or (disease) habitat. As in our previous study, there was again strong evidence that the relation among the isolates was distorted by recombination. We observed a network of relationships between all analysed parameters (Figure 1, Figure 2, Figure 3, Figure 4) and a relatively low congruence between experiments (Figure 5). Evidence of recombination is additionally supported by the mosaic structure of the *oprD* gene (http://www.pseudomonas.com/related_links.jsp#alleles), which is the result of a history of intra and possibly inter species recombinational exchanges of DNA blocks [74]. We also observed several conserved clones, characterized by an almost identical data set (Figure 1, Figure 2, Figure 3, Figure 4) and represented by relatively large numbers of isolates (circles) in the MST (Figure 7). The results of this

polyphasic characterization confirm the nonclonal epidemic population structure of *P. aeruginosa*, i.e. a superficially clonal structure with frequent recombinations, in which occasionally highly successful epidemic clones arise.

A conventional UPGMA dendrogram based on the composite similarity matrix is shown in Figure S2.

CF “transmissible” clones

According to this study, a typical CF strain shows the following profile: non- or polyagglutinable (76.5%), *oprD* group B (93.0%), *oprL* group B (97.7%), *exoS*⁺ (97.7%) and *flpB*⁺ (100%) (Table 3). Although CF isolates exhibited a genetic diversity that was comparable to that observed in other habitats, all of them, with the exception of Li004, clustered in, or were located at the border of what appears to be a large ‘core lineage’ (Figure 7). This ‘core lineage’ seems to be predominant in disease and environmental habitats across the world and is composed of CCs A, D and J (Figure 7). Li004 was isolated from a CF patient in Lisbon (Figure 3), but it remains unclear whether it is an ‘early’

Table 5. Defective *oprD* mutations (DOMs) in 328 *P. aeruginosa* isolates.

DOM	Strain	Mutation
1	Be128	Large deletion starting from NT 874 and covering the termination codon
2	Is573	C→T base substitution at NT 1018 → premature termination
3	Aa245	C→T base substitution at NT 1243 → premature termination
4	Bu007	G→T base substitution at NT 511 → premature termination
5	C19	G→A base substitution at NT 413 → premature termination
6	Li010	G→A base substitution at NT 831 → premature termination
7	Aa249	T→C base substitution at NT 32 → leucine replaced by proline in signal peptide
8	Br670	T→C base substitution at NT 1076 → leucine replaced by proline in external loop 7
9	Br718	Duplication between GCGCGG repeats (NT 573-8 and 617-22) → frameshift → stop codon at NT 730-2
10	Pr317	1-base duplication at monotonic repeat CCCC (NT 346-9) → frameshift → stop codon at NT 352-4
11	Mi162	1-base deletion at monotonic repeat CCCC (NT 346-9) → frameshift → stop codon at NT 379-81
12	Bo548	1-base deletion at monotonic repeat GGGGG (NT 631-5) → frameshift → stop codon at NT 713-5
13	Br993/678	Large deletion covering initiation codon
14	PHLS08960	A→T base substitution at NT 886 → premature termination
15	LUH7552	Duplication of GCC at NT 859-62 → frameshift → stop codon at NT 913-5
16	KAT3529	Deletion of A at NT 1082 → frameshift → stop codon at NT 1294-6
17	MC116	Deletion of AA at NT 820-1 → frameshift → stop codon at NT 1090-2
18	MC039	C→T base substitution at NT 883 → premature termination
19	MC325	Duplication of C at NT 540 → frameshift → stop codon at NT 580-2
20	1709-12	G→A base substitution at NT 195 → premature termination
21	PN1296	Deletion of G at NT 423 frameshift → stop codon at NT 713-5

NT, nucleotide.

doi:10.1371/journal.pone.0007740.t005




Figure 7. Minimum spanning tree of the similarity matrix of the composite data set consisting of the FALP pattern, serotype, *oprI*, *oprL*, and *oprD* gene sequences, pyoverdine receptor profile and prevalence of *exoS/U* for 328 *P. aeruginosa* strains. Each circle corresponds to a polyphasic profile (PP). The circles are scaled with member count. Branch lengths are logarithmic. Coloured zones surround PPs that belong to the same clonal complex. These complexes are also indicated with a capital letter. The lines between PPs indicate inferred phylogenetic relationships and are represented as bold, plain, discontinuous and light discontinuous depending on the number of differences between profile types. Discontinuous links are only indicative. Two bold black indent lines delimit the *P. aeruginosa* "core lineage"; the MDR serotype O12 clone is encircled by a red dotted line.
doi:10.1371/journal.pone.0007740.g007

sporadic strain or a 'late' persistent strain. All characteristics that were associated with the CF niche (*exoS*, group B *oprL*, group B *oprD*, *fpvA* type II and presence of *fpvB*) in this study were also prevalent in this 'core lineage'. This supports the argument that not one parameter in

itself, but rather a multitude of linked characteristics are responsible for the selection of particular strains in the CF niche.

Although CF strains isolated in different locations across the world were shown to be genotypically non-identical and thus

probably not directly related (Figure 1, Figure 2, Figure 3, Figure 4, and Figure 7), they all clustered into the 'core lineage'. It is thus quite understandable that CF strains isolated in distant places show some level of relatedness, which should however not be confused with clonality. Lanotte *et al.* determined some genetic features of 162 isolates from different ecological origins [111] and found that 3 major genogroups of *P. aeruginosa* isolates were able to colonize CF patients. Unfortunately, due to different choices of typing techniques and strains between studies, we are not able to match these genogroups to our clonal complexes.

Occasional transmission of CF strains in CF clinics and holiday or rehabilitation camps has been reported [37,112,113]. Our results indicate that a widespread or global transmission of successful *P. aeruginosa* CF strains is unlikely to have occurred. Our data suggest that strains belonging to the successful 'core lineage' are ubiquitous in the natural environment and are therefore more likely to infect CF patients. In 1994, Römling *et al.* observed that clone C, the major clone in the CF population in Germany, was also overrepresented in soil and aquatic habitats, and suggested that the isolation frequency in CF patients simply reflected the distribution of clones in the environment [3].

MDR serotype O11 and O12 strains

All confirmed MDR O12 strains, showing resistance to one or more representatives of at least 3 antibiotic classes (Figure 1, Figure 2, Figure 3, Figure 4), clustered into a very conserved clone (Figure 7). These strains typically exhibited the following profile: serotype O12 (100%), *oprD* group A (100%), *oprL* group B (100%), *oprI* group B (100%), *exoS*⁺ (100%), *ffpB*⁺ (100%) and *tfpOb*⁺ (100%) (Figure 1, Figure 2, Figure 3, Figure 4, and Table 3). MDR serotype O11 strains, in contrast, clustered into CCs F, G, H and I (Figure 7) and showed an overall higher genetic divergence (Figure 1, Figure 2, Figure 3, Figure 4, and Table 3). Serotyping of 7089 *P. aeruginosa* strains, isolated in 16 Belgian hospitals in the period from 1977 to 1986, revealed a steady increase of *P. aeruginosa* O12 isolates from 2% in 1982 to 22% in 1986 [114]. The majority of these O12 isolates showed the same distinctive pyocin and phage types, suggesting a high degree of homogeneity within the O12 strains in Belgium. A multicentre European study provided evidence for a common O12 *P. aeruginosa* strain in Europe [41]. In the present study, all MDR O12 strains, isolated between 1985 and 2006 in 9 countries, some of them separated by thousands of miles, were shown to cluster into a very conserved clone exhibiting virtually no divergence after more than 20 years of 'evolution' (Figure 1, Figure 2, Figure 3, Figure 4, and Figure 7). This MDR O12 clone consists exclusively of clinical isolates; absolutely no environmental, animal or CF isolates were part of this clone (Figure 7). Furthermore, only recent strains, isolated post 1980, clustered into this clone (Figure 1, Figure 2, Figure 3, Figure 4, and Table 3). These observations could be indicative of a recent, rapid and widespread dissemination. Natural forces are likely to sustain global dispersal of organisms as small and abundant as bacteria [115], but the increased mobility of humans and the simultaneous worldwide increase of high care facilities is likely to have accelerated the dispersal of these MDR epidemic strains. One could state that the MDR O12 clone is a genuine global epidemic clone. Strains can acquire characteristics (e.g. antibiotic resistance determinants), which are advantageous in a specific niche (e.g. an intensive care unit) and this can lead to a rapid clonal expansion. The O12 clone was, to the best of our knowledge, never isolated from the natural environment and it has been suggested that colonised or infected patients might be the primary reservoirs of the prevalent O12 clone [54,116].

We feel that the emerging MDR O12 clone is an example of a rapid and sustained adaptation of *P. aeruginosa* to a novel

environment. Man-made changes to the (hospital) environment, like the introduction of antimicrobials, are affecting the *P. aeruginosa* population structure.

Conclusion

This present study is to our knowledge the first report of an MST analysis conducted on a polyphasic data set. The population structure of *P. aeruginosa* was determined by means of a combination of seven valuable experiments. Analysis and clustering based on a single experiment broadly conserved the clonal complexes and clones designated in the MST based on the combined experiments (Figure 1, Figure 2, Figure 3, Figure 4). The relationship between these groups of strains, however, varied according to the considered experiment, which is visualized as a mosaic pattern in Figure 1, Figure 2, Figure 3, Figure 4. Therefore, we are convinced that the ultimate or 'true' population structure is most faithfully approached combining as many experiments as feasible, which are then again performed on as many unrelated and diverse strains as feasible.

This polyphasic characterization of 328 diverse and unrelated *P. aeruginosa* strains confirmed the nonclonal epidemic population structure of *P. aeruginosa*. Our results also indicate that there are no widespread CF epidemic clones. CF strains are part of a successful and ubiquitous 'core lineage' that have infected CF patients from the natural environment and spread through short to medium range transmission between patients in CF clinics and holiday and rehabilitation camps, possibly helped by breaches in basic infection control measures. In contrast, we report the worldwide spread and persistence of MDR clone O12. The excessive use of antibiotics has caused a worldwide 'unnatural' selection for multiply resistant or even panresistant *P. aeruginosa* strains.

We hope that the evolutionary framework presented in this study will serve as the basis for more specific studies that will prove helpful in designing public health policies (e.g. segregation of CF patients or not). Additionally, the exchange of standardized data between laboratories and the creation of international reference databases of typed microorganisms should be encouraged. It will enable an efficient monitoring of changes in microbial populations and consequently allow more adequate infection control measures. Knowing a species population structure and evolutionary paths is the cornerstone of strategies aiming to control it. Specialised follow-up papers, based on the evolutionary framework presented here and dealing with some clinically relevant issues, are in preparation.

Materials and Methods

P. aeruginosa isolates

A total of 328 *P. aeruginosa* clinical and environmental isolates, collected worldwide (69 localities, 30 countries and 5 continents) were examined (Table 1).

Most of them were isolated in the late eighties and nineties, but 49 were isolated before 1980, including 14 *P. aeruginosa* strains isolated at the 'Institut Pasteur' in Paris by Carle Gessard [1] and his colleagues in the late 19th century. The studied collection contained 185 human clinical isolates (including 43 CF, 33 burn, 32 wound, 18 urine, 15 sputum, 6 faeces and 5 blood isolates), 63 animal clinical isolates (39 dogs, 6 turtles, 4 horses, 3 parrots, 3 dolphins, 2 cats, 2 cows, 1 kangaroo, 1 goat, 1 rabbit and 1 seal) and 55 environmental isolates (17 sea water, 16 river water, 6 lake water, 5 turtle egg, 4 plant, 3 tap water, 2 swimming pool water and 2 drink water isolates). Geographical origin, isolation site and time and other relevant characteristics of all *P. aeruginosa* isolates can be found in Figure 1, Figure 2, Figure 3, Figure 4.

The *P. aeruginosa* strains were kindly provided by: Dr. A. T. McManus, US Army Institute of Surgical Research, Texas, USA; Dr. L. Ménesi, General Hospital St. Istvan, Budapest, Hungary; Dr. A. Vanderkelen, Dr. S. Jennes, G. Verbeken and D. Schoeters, Queen Astrid Military Hospital, Neder-Over-Heembeek (Brussels), Belgium; Dr. J. A. Clark, Queen Mary's University Hospital, London, England; Dr. A. F. Vloemans, Rode Kruis Ziekenhuis, Beverwijk, The Netherlands; Dr. T. Taddonio, University of Michigan, Michigan, USA; Dr. A. Radke, Klinik für Verbrennungs- und Plastische Wiederherstellungschirurgie, Aachen, Germany; Prof. R. Konigova, Charles University Hospital, Prague, Czech Republic; Dr. R. G. Tompkins, Burns Institute, Shriners Hospital for Children, Boston, USA; Prof. B. Tümmler, Medizinische Hochschule, Hannover, Germany; Dr. M. Caneira, Hospital de Santa Maria, Lisboa, Portugal; Prof. A. Boudabous, Science Faculty, Tunis, Tunisia; Dr. M. Mergeay, Environmental Technology Expertise Centre, Mol, Belgium; Dr. A. E. Lim Jr., St. Scholastica's College of Health Sciences, Tacloban City, Philippines; Prof. O. Hadjiiski, Scientific Institute of Emergency Medicine Pirogov, Sofia, Bulgaria; Prof. K. Taviloglu, University of Istanbul, Istanbul, Turkey; Dr. W. D. H. Hendriks, Zuiderziekenhuis, Rotterdam, The Netherlands; Dr. G. Wauters, University of Louvain, Brussels, Belgium; Dr. O. Vandenberg, Universitair Ziekenhuis St.-Pierre, Brussels, Belgium; Prof. M. Vaneechoutte, University Hospital Ghent, Gent, Belgium; Prof. J. Van Eldere, Catholic University of Leuven, Leuven, Belgium; Dr. U. Römling, Karolinska Institute, Stockholm, Sweden; Dr. L. Roddam and R. Bradbury, University of Tasmania, Hobart, Australia; Dr. T. L. Pitt, Health Protection Agency, London, UK; Dr. A. Leitão, Faculty of Veterinary Medicine, Lisboa, Portugal; Dr. R. W. Brimicombe, Haga Ziekenhuis, Den Haag, The Netherlands; Prof. N. J. Legakis and Dr. P. T. Tassios, National and Kapodastrian University of Athens, Athens, Greece; Prof. J.-M. Meyer, University Louis Pasteur, Strasbourg, France and Dr. M. P. Crespo, Universidad Santiago de Cali, Cali, Colombia; Dr. M. Merabishvili and Dr. Nina Chanishvili, Eliava Institute, Tbilisi, Georgia; Dr. L. Griffiths, Dr. K. Craven and J. Awong-Taylor, Armstrong Atlantic State University, Savannah, US; Prof. M. de Chial, University of Panama, Panama City, Panama; Dr. N. H. Khan, Dr. N. Kimata and Prof. K. Kogure, University of Tokyo, Tokyo, Japan; Dr. D. Armstrong, Monash Medical Center, Melbourne, Australia; A. Catrijsse, Vlaams Instituut voor de Zee, Oostende, Belgium.

Strains LMG 2107, 5031, 10643, and 14083-5 were purchased from the BCCMTM/LMG bacteria collection. The 20 'CPHL (Central Public Health Laboratory) strains' were purchased from the National Collection of Type Cultures in London (UK). Strain PAO-1 was kindly provided by Dr. C. K. Stover (PathoGenesis Corporation, Seattle, USA). Strain ATCC 27853 was purchased from Gibson Laboratories (USA).

All isolates were grown overnight in Luria-Bertani broth medium (Gibco-BRL-Life Technologies, Belgium) at 37°C on a rotary shaker (150 rpm). The overnight cultures were mixed with equal amounts of sterile 50% (vol/vol) glycerol (Sigma Aldrich, Belgium) in PBS buffer (Sigma Aldrich, Belgium) and stored in duplicate at -80°C.

FAFLP

FAFLP utilized an ABI 377 automated fluorescence sequencer (Applied Biosystems, Belgium), and the AFLPTM Microbial Fingerprinting Kit (Applied Biosystems) as detailed in the manufacturer's protocols. The enzymes used were T4 DNA ligase, *EcoRI*, and *Tru9I* (all purchased from Roche Diagnostics, Belgium). The primer pair used was *EcoRI*-0[FAM]/*MseI*-C.

GeneScan-500[ROX] internal standard (Applied Biosystems) was co-electrophoresed with each sample in order to allow an accurate calculation of fragment lengths and correction for variation rates and gel distortions. Normalization and fragment sizing were carried out using GeneScan software (Applied Biosystems, Belgium). Band patterns were imported into the BioNumerics v5.1 software (Applied Maths, Belgium) and normalised; parameters used: background subtraction (10% disc diameter), filtering (arithmetic average), band search (minimum profiling 0.5% relative to the maximum value). Cluster analysis was performed by pairwise calculation of the Pearson correlation; the similarity matrix was clustered using the UPGMA algorithm with optimization: 0%, position tolerance: 1%; uncertain bands were ignored.

Serotyping

Strains were grown overnight on Luria-Bertani agar medium (Gibco-BRL-Life Technologies) at 37°C. Isolates were serotyped by slide agglutination according to the International Antigenic Typing Scheme (IATS) for *P. aeruginosa* [117], using a panel of 16 type O monovalent antisera (Bio-Rad, Belgium). Some strains had already been serotyped by the strain providers (e.g. isolates LMG 14084 and CPHL 12447, which were shown to exhibit the provisional O17 and O18 serotypes).

PCR and sequencing

Strains were grown overnight in Luria-Bertani broth medium (Gibco-BRL-Life Technologies) at 37°C on a rotary shaker (150 rpm). DNA was extracted from the overnight cultures using the High PureTM PCR Template Preparation Kit (Roche Diagnostics) according to the manufacturer's guidelines. The complete *oprI*, *oprL*, and *oprD* genes and a fragment of the *exoS*, *exoU*, *fpvA*, *fpvB* and *tffO* genes were amplified by PCR, using the primers described in Table 6. PCR was performed in 200- μ l microcentrifuge tubes. The PCR mixture (50 μ l final volume) contained the following: 25.5 μ l sterile distilled water, 5 μ l 10 \times PCR buffer (500 mmol/l KCl and 100 mmol/l Tris-HCl: pH 8.3), 4 μ l of a deoxynucleotide mixture (dGTP, dTTP, dATP, and dCTP; 2 mmol/l each), 5 μ l MgCl₂ (2.5 mmol/l), 5 μ l of a primer mixture (10 μ mol/l each), 5 μ l template DNA, and 0.5 μ l AmpliTaq DNA polymerase (5 U/ μ l). All PCR-reagents and primers were ordered from PE-Applied Biosystems. The amplification was performed in a GeneAmp[®] 9700 thermocycler (Applied Biosystems). The amplification program was set at 50 cycles of denaturation at 94°C for 30 s, annealing at a temperature in accordance to the primers (Table 6), for 30 s, and elongation at 72°C for 1 min. In a few strains the amplification of the *fpvA* gene required degenerate primers. The reaction mixture was put on an agarose gel of 1.5 % (wt/vol) for electrophoresis and visualization of the PCR-product after staining with ethidium bromide on a transilluminator. Prior to the sequencing of the *oprD*, *oprL* and *oprI* genes, the respective PCR-products were purified, using centri-con[®] 100 micro-concentrators (Millipore, Brussels, Belgium) according to the manufacturer's instructions. Five μ l of the purified PCR fragment was used as a template in the sequencing reaction. PCR primers were used for sequencing. Sequencing of the coding and anti-coding strand of the *oprD* PCR products necessitated two additional internal primers (Table 6). DNA sequencing utilized an ABI 377 automated fluorescence sequencer (Applied Biosystems), and the ABI Prism[®] BigDyeTM Terminator cycle sequencing kit (Applied Biosystems) as detailed in the manufacturer's protocols. The *oprD* gene of isolate Be128 was sequenced directly from genomic DNA. Some genes were sequenced in the VIB Genetic Service Facility (Belgium) using a capillary Applied Biosystems 3730 DNA Analyzer. PCR and

Table 6. Primers for PCR and sequencing.

Target	Primer	Sequence (5' to 3')	Tm (°C)	Size (bp)	Reference
<i>oprI</i>	PS1	ATGAACAACGTTCTGAAATTCTCTGCT	57	248	[70]
	PS2	CTTGC GGCTGGCTTTTCCAG			
<i>oprL</i>	PAL1	ATGGAATGCTGAAATTCGGC	57	504	[70]
	PAL2	CTTCTCAGCTCGACGCGACG			
<i>oprD</i>	DF1	ATGAAAGTGATGAAGTGGAGC	49	1323-9	[13]
	DR1	CAGGATCGACAGCGGATAGT			
<i>oprD</i> (for sequencing)	DF2	AACCTCAGCGCTCCCT	49	NA	[13]
	DR2	AGGGAGGCGCTGAGGTT			
<i>fpvA I</i>	<i>fpvAlf</i>	CGAACCCGACGAAGGCCAGA	52	324	[81]
	<i>fpvAlr</i>	GTAGCTGGTGTAGAGGCTCAA			
<i>fpvA IIa</i>	<i>fpvAllaf</i>	TACCTCGACGGCCTGCACAT	52	908	[81]
	<i>fpvAllar</i>	GAAGGTGAATGGCTTGCCGT			
<i>fpvA IIb</i>	<i>fpvAllbf</i>	GAACAGGGCACCTACCTGTA	52	863	[81]
	<i>fpvAllbr</i>	GATGCCGTTGCTGAACTCGTA			
<i>fpvA III</i>	<i>fpvAlllf</i>	ACTGGGACAAGATCCAAGAGA	52	505	[81]
	<i>fpvAlllr</i>	CTGGTAGGACGAAATGCGA			
<i>fpvB</i>	<i>fpvBf</i>	GCATGAAGCTCGACCAGGA	52	562	[81]
	<i>fpvBr</i>	TTGCCCTCGTTGGCCTTG			
<i>exoS</i>	<i>exoSF</i>	TCAGGTACCCGGCATTCACTACGCGG	55	572	[98]
	<i>exoSR</i>	TCACTGCAGGTTCTGACGCTTTCTTTTA			
<i>exoU</i>	<i>exoUF</i>	AGCGTTAGTGACGTGCG	55	1572	[98]
	<i>exoUR</i>	GCGCATGGCATCGAGTAAGT			
<i>tfpO_a</i>	<i>tfpOup</i>	CGTACTATTCTATTATTGCTGA	55	849	[86]
	<i>tfpOdown</i>	CAAAGGATGGGCTACGAA			
<i>tfpO_b</i>	<i>tfpO2up</i>	CTGATGCTGTTTCTTC	55	551	[86]
	<i>tfpO2down</i>	GCATCTCGCCACAACACG			

Tm: annealing temperature.

doi:10.1371/journal.pone.0007740.t006

sequencing were performed in duplicate in order to be able to detect eventual PCR mistakes.

Using the BioNumerics v5.1 software, sequences were grouped via a pairwise clustering (pairwise alignment parameters: open gap penalty: 100%, unit gap penalty: 0%, min. match sequence: 2, max n° of gaps: 9, fast algorithm). The obtained UPGMA tree was used to seed a multiple alignment (multiple alignment parameters: open gap penalty: 100%, unit gap penalty: 0%, min. match sequence: 2, max n° of gaps: 98). Finally, multiple aligned sequences were clustered using the same parameters as used in the initial pairwise clustering, resulting in the final UPGMA tree.

Combined data analysis

A data set consisting of the serotype, FAFLP pattern, *oprI*, *oprL*, and *oprD* gene sequences, pyoverdine receptor profile (*fpvA* and *fpvB*) and prevalence of the genes *exoS* and *exoU* of 328 *P. aeruginosa* isolates was analyzed using the biological data analysis software BioNumerics v5.1. The settings used for the comparison of the FAFLP fingerprints and the gene sequences are described in the respective paragraphs. Serotype, pyoverdine receptor profile and presence of *exoS/U* were compared using the Pearson correlation. These individual comparisons resulted in individual similarity matrices, which were averaged into the similarity matrix of the composite data set. No correction for internal weights was applied. Each isolate was thus assigned a 'polyphasic profile' (PP)

contributing to the composite similarity matrix. Grouping of the averaged composite similarity matrix was achieved by MST analysis using BioNumerics v5.1 software. The MST coefficient was taken from the composite similarity matrix. The Degeneracy of the MST was reduced through the use of a priority rule by which types that had a maximum number of entries were linked first, confirming a biological meaning that these clones are most likely older. For visual purposes, isolates were further grouped into clonal complexes. For the creation of the clonal complexes, the similarity bin size (1 change) was set to 2.5%; the maximal neighbour distance between two complexes was 5 changes (12.5%) and the minimum size of a complex was 5 types. Originally a clonal complex was defined as a cluster of STs in a burstdiagram in which all STs are linked as SLVs to at least one other ST. In our case a clonal complex is a cluster of PPs, after MST analysis, in which all PPs with less than 5 changes (= less than 12.5% distance in the similarity matrix) are linked. Congruence between experiments was calculated using the Pearson product-moment correlation coefficient between the respective similarity matrices.

Antimicrobial susceptibility tests

Strains were grown 18–24 h at 37°C on Columbia agar containing 5% horse blood (bioMérieux). Suspensions of these cultures were made in 0.45% saline, adjusted to the turbidity of a

0.6 McFarland standard, and used to load the test cards for VITEK 2 (bioMérieux), which was used in accordance with the manufacturer's directions. The following antibiotics were tested using the AST-N020 antimicrobial susceptibility cards: AMP, ampicillin; AMC, amoxicillin + clavulanic acid; PIP, piperacillin; TZP, piperacillin + tazobactam; CEF, cephalothin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; CPD, cefpodoxime; FOX, cefoxitin; FEP, cefepime; MEM, meropenem; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; NOR, norfloxacin; OFX, ofloxacin; CIP, ciprofloxacin; NIT, nitrofurantoin; SXT, trimethoprim + sulfamethoxazole. Antibiotic resistance phenotypes, represented by the minimum inhibitory concentrations (MICs) for the above-mentioned antibiotics, were determined using VITEK 2 Advanced Expert System (AES) [118]. *P. aeruginosa* ATCC 27853 was used as control strain. For some isolates the MIC was determined by the broth microdilution method [119].

Nucleotide sequences

The nucleotide sequences generated in this study have been deposited in the *Pseudomonas aeruginosa* Genome database (http://www.pseudomonas.com/related_links.jsp#alleles).

Strain collection

All studied *P. aeruginosa* strains were deposited in the Belgian Coordinated Collections of Microorganisms (BCCM) of the Laboratorium voor Microbiologie (LMG) of the Ghent University. Strains were assigned a BCCM/LMG number (LMG 24881 - 25202). Strains that were obtained from a culture collection

(BCCM/LMG or ATCC) maintained their original reference number.

Strains can be obtained from the LMG bacteria collection for research use only and with the consent of the strain donors.

Supporting Information

Figure S1 UPGMA dendrogram of the FAFLP patterns of the 328 studied *P. aeruginosa* strains.

Found at: doi:10.1371/journal.pone.0007740.s001 (0.42 MB PDF)

Figure S2 UPGMA dendrogram of the similarity matrix of the composite data set consisting of the serotype, FAFLP pattern, *oprI*, *L*, and *D* gene sequences, pyoverdine receptor profile and prevalence of *exoS/U* genes for the 328 studied *P. aeruginosa* strains.

Found at: doi:10.1371/journal.pone.0007740.s002 (0.02 MB PDF)

Acknowledgments

We thank all the collectors and providers of *P. aeruginosa* isolates.

Author Contributions

Conceived and designed the experiments: JPP PC DDV. Performed the experiments: JPP FB. Analyzed the data: JPP FB BP PC MZ JVE PD MV SJ TP DDV. Contributed reagents/materials/analysis tools: JPP BP PC MZ JVE PD MV SJ TP DDV. Wrote the paper: JPP BP PC MZ JVE MV SJ TP DDV.

References

- Gessard C (1882) Sur les colorations bleue et verte des linges à pansements. Comptes-rendus hebdomadaire des séances de l'Académie des Sciences 94: 536–538.
- Goldberg JB (2000) *Pseudomonas*: global bacteria. Trends Microbiol 8: 55–57.
- Römling U, Wingender J, Müller H, Tümmler B (1994) A major *Pseudomonas aeruginosa* clone common to patients and aquatic habitats. Appl Environ Microbiol 60: 1734–1738.
- Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, et al. (1995) Common virulence factors for bacterial pathogenicity in plants and animals. Science 268: 1899–1902.
- Foght JM, Westlake DWS, Johnson WM, Ridgway HF (1996) Environmental gasoline-utilizing isolates of *Pseudomonas aeruginosa* are taxonomically indistinguishable by chemotaxonomic and molecular techniques. Microbiology 142: 2333–2340.
- Alonso A, Rojo F, Martinez JL (1999) Environmental and clinical isolates of *Pseudomonas aeruginosa* show pathogenic and biodegradative properties irrespective of their origin. Environ Microbiol 1: 421–430.
- Maynard Smith J, Smith NH, O'Rourke M, Spratt BG (1993) How clonal are bacteria? Proc Natl Acad Sci U S A 90: 4384–4388.
- Denamur E, Picard B, Decoux G, Denis JB, Elion J (1993) The absence of correlation between allozyme and rrr RFLP analysis indicates a high gene flow rate within human clinical *Pseudomonas aeruginosa* isolates. FEMS Microbiol Lett 110: 275–280.
- Picard B, Denamur E, Barakat A, Elion J, Goulet P (1994) Genetic heterogeneity of *Pseudomonas aeruginosa* clinical isolates revealed by esterase electrophoretic polymorphism and restriction fragment length polymorphism of the ribosomal RNA gene region. J Med Microbiol 40: 313–322.
- Kiewitz C, Tümmler B (2000) Sequence diversity of *Pseudomonas aeruginosa*: impact on population structure and genome evolution. J Bacteriol 182: 3125–3135.
- Ruimy R, Genauzeau E, Barnabe C, Beaulieu A, Tibayrenc M, et al. (2001) Genetic diversity of *Pseudomonas aeruginosa* strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Infect Immun 69: 584–588.
- Lomholt JA, Poulsen K, Kilian M (2001) Epidemic population structure of *Pseudomonas aeruginosa*: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect Immun 69: 6284–6295.
- Pirnay JP, De Vos D, Cochez C, Bilocq F, Vanderkelen A, et al. (2002) *Pseudomonas aeruginosa* displays an epidemic population structure. Environ Microbiol 4: 898–911.
- Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG (2004) Development of a multilocus sequence typing scheme for the opportunistic pathogen *Pseudomonas aeruginosa*. J Clin Microbiol 42: 5644–5649.
- Pirnay JP, Matthijs S, Colak H, Chablain P, Bilocq F, et al. (2005) Global *Pseudomonas aeruginosa* biodiversity as reflected in a Belgian river. Environ Microbiol 7: 969–980.
- Spencer DH, Kas A, Smith EE, Raymond CK, Sims EH, et al. (2003) Whole-genome sequence variation among multiple isolates of *Pseudomonas aeruginosa*. J Bacteriol 185: 1316–1325.
- Wolfgang MC, Kulasekara BR, Liang X, Boyd D, Wu K, et al. (2003) Conservation of genome content and virulence determinants among clinical and environmental isolates of *Pseudomonas aeruginosa*. Proc Natl Acad Sci U S A 100: 8484–8489.
- He J, Baldini RL, Déziel E, Saucier M, Zhang Q, et al. (2004) The broad host range pathogen *Pseudomonas aeruginosa* strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 101: 2530–2535.
- Morales G, Wiehmann L, Gudowius P, van Delden C, Tümmler B, et al. (2004) Structure of *Pseudomonas aeruginosa* populations analyzed by single nucleotide polymorphism and pulsed-field gel electrophoresis genotyping. J Bacteriol 186: 4228–4237.
- Mathec K, Narasimhan G, Valdes C, Qiu X, Matewish JM, et al. (2008) Dynamics of *Pseudomonas aeruginosa* genome evolution. Proc Natl Acad Sci U S A 105: 3100–3105.
- Shen K, Sayeed S, Antalis P, Gladitz J, Ahmed A, et al. (2006) Extensive genomic plasticity in *Pseudomonas aeruginosa* revealed by identification and distribution studies of novel genes among clinical isolates. Infect Immun 74: 5272–5283.
- Ripp S, Ogunseitian OA, Miller RV (1994) Transduction of a freshwater microbial community by a new *Pseudomonas aeruginosa* generalized transducing phage, UT1. Mol Ecol 3: 121–126.
- Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, et al. (2006) Genomic analysis reveals that *Pseudomonas aeruginosa* virulence is combinatorial. Genome Biol 7: R90.
- Wiehmann L, Wagner G, Cramer N, Siebert B, Gudowius P, et al. (2007) Population structure of *Pseudomonas aeruginosa*. Proc Natl Acad Sci U S A 104: 8101–8106.
- Farmer JJ 3rd, Weinstein RA, Zierdt CH, Brokopp CD (1982) Hospital outbreaks caused by *Pseudomonas aeruginosa*: Importance of serogroup O11. J Clin Microbiol 16: 266–270.
- Giammanco A, Di Stefano R, Arista S, Sinatra A, Chiarini A (1985) Infections caused by *Pseudomonas aeruginosa*: relatively frequent isolation of serogroup 12 from clinical specimens. Eur J Epidemiol 1: 104–109.
- Legakis NJ, Koukoubanis N, Malliara K, Michalitsianos D, Papavassiliou J (1987) Importance of carbenicillin and gentamicin cross-resistant serotype O:12 *Pseudomonas aeruginosa* in six Athens hospitals. Eur J Clin Microbiol 6: 300–303.

28. Pitt TL, Livermore DM, Pitcher D, Vatopoulos AC, Legakis NJ (1989) Multiresistant serotype O12 *Pseudomonas aeruginosa*: evidence for a common strain in Europe. *Epidemiol Infect* 103: 565–576.
29. Grattard F, Gaudin OG, Pozzetto B, Ros A, Mbida AD (1993) Genotypic homogeneity of nosocomial *Pseudomonas aeruginosa* O12 strains demonstrated by analysis of protein profiles, DNA fingerprints and rRNA gene restriction patterns. *Eur J Clin Microbiol Infect Dis* 12: 57–61.
30. Tsakris A, Vatopoulos AC, Tzouveleki LS, Legakis NJ (1992) Diversity of resistance phenotypes and plasmid analysis in multi-resistant O:12 *Pseudomonas aeruginosa*. *Eur J Epidemiol* 8: 865–870.
31. Elaichouni A, Verschraegen G, Claeys G, Devleschouwer M, Godard C, et al. (1994) *Pseudomonas aeruginosa* serotype O12 outbreak studied by arbitrary primer PCR. *J Clin Microbiol* 32: 666–671.
32. Richard P, Le Floch R, Chamoux C, Pannier M, Espaze E, et al. (1994) *Pseudomonas aeruginosa* outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. *J Infect Dis* 170: 377–383.
33. Kettner M, Milosovic P, Hletková M, Kallová J (1995) Incidence and mechanisms of aminoglycoside resistance in *Pseudomonas aeruginosa* serotype O11 isolates. *Infection* 23: 380–383.
34. Bingen E, Bonacorsi S, Rohrllich P, Duval M, Lhopital S, et al. (1996) Molecular evidence of genotypic heterogeneity of multidrug-resistant *Pseudomonas aeruginosa* serotype O:12 outbreak isolates from a pediatric hospital. *J Clin Microbiol* 34: 3226–3229.
35. Mišud AJ, Watine J, Picard B, Charet JC, Solignac-Bourrel C, et al. (1997) Epidemiologically related and unrelated strains of *Pseudomonas aeruginosa* serotype O12 cannot be distinguished by phenotypic and genotypic typing. *J Hosp Infect* 36: 105–116.
36. Tassios PT, Gennimata V, Maniatis AN, Fock C, Legakis NJ, et al. (1998) Emergence of multidrug resistance in ubiquitous and dominant *Pseudomonas aeruginosa* serogroup O:11. *J Clin Microbiol* 36: 897–901.
37. Watine J, Hacin J, Vidal I (1999) Is there a connection between prolonged carriage and clonal hospital-to-hospital clonal spread of multiresistant *Pseudomonas aeruginosa* of the O12 serotype? Are the specific habits of the hospitals involved the cause? *Pathol Biol (Paris)* 47: 457–461.
38. Müller-Premru M, Gubina M (2000) Serotype, antimicrobial susceptibility and clone distribution of *Pseudomonas aeruginosa* in a university hospital. *Zentralbl Bakteriol* 289: 857–867.
39. Dubois V, Arpin C, Melon M, Melon B, Andre C, et al. (2001) Nosocomial outbreak due to a multiresistant strain of *Pseudomonas aeruginosa* P12: efficacy of cefepime-amikacin therapy and analysis of β -lactam resistance. *J Clin Microbiol* 39: 2072–2078.
40. Loureiro MM, de Moraes BA, Mendonca VL, Quadra MR, Pinheiro GS, et al. (2002) *Pseudomonas aeruginosa*: study of antibiotic resistance and molecular typing in hospital infection cases in a neonatal intensive care unit from Rio de Janeiro City, Brazil. *Mem Inst Oswaldo Cruz* 97: 387–394.
41. Pirnay JP, De Vos D, Cochez C, Bilocq F, Pirson J, et al. (2003) Molecular epidemiology of *Pseudomonas aeruginosa* colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. *J Clin Microbiol* 41: 1192–1202.
42. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, et al. (2004) Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-3, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. *J Clin Microbiol* 42: 5094–5101.
43. Deplano A, Denis O, Poirel L, Hocquet D, Nonhoff C, et al. (2005) Molecular characterization of an epidemic clone of panantibiotic-resistant *Pseudomonas aeruginosa*. *J Clin Microbiol* 43: 1198–1204.
44. Riccio ML, Pallechi L, Docquier JD, Cresti S, Catania MR, et al. (2005) Clonal relatedness and conserved intergen structures in epidemiologically unrelated *Pseudomonas aeruginosa* strains producing the VIM-1 metallo- β -lactamase from different Italian hospitals. *Antimicrob Agents Chemother* 49: 104–110.
45. Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Kasai A, Mizuguchi Y, et al. (2007) Outbreaks of multidrug-resistant *Pseudomonas aeruginosa* in community hospitals in Japan. *J Clin Microbiol* 45: 979–989.
46. Hammami S, Ghozzi R, Burghoffer B, Arlet G, Redjeb S (2008) Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of *Pseudomonas aeruginosa* from a Tunisian hospital. *Pathol Biol (Paris)* Oct 30 [Epub ahead of print].
47. Libisch B, Watine J, Balogh B, Gacs M, Muzslay M, et al. (2008) Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing *Pseudomonas aeruginosa* clinical isolates in Hungary. *Res Microbiol* 159: 162–168.
48. Cheng K, Smyth RL, Govan JRW, Doherty C, Winstanley C, et al. (1996) Spread of β -lactam-resistant *Pseudomonas aeruginosa* in a cystic fibrosis clinic. *Lancet* 348: 639–642.
49. Fluge G, Ojemi B, Hoiby N, Digranes A, Ciofu O, et al. (2001) Typing of *Pseudomonas aeruginosa* strains in Norwegian cystic fibrosis patients. *Clin Microbiol Infect* 7: 238–243.
50. Jones AM, Govan JRW, Doherty CJ, Dodd ME, Isalska BJ, et al. (2001) Spread of a multiresistant strain of *Pseudomonas aeruginosa* in an adult cystic fibrosis clinic. *Lancet* 358: 557–558.
51. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ (2001) Superinfection with a transmissible strain of *Pseudomonas aeruginosa* in adults with cystic fibrosis chronically colonised by *P. aeruginosa*. *Lancet* 358: 558–560.
52. Anthony M, Rose B, Pegler MB, Elkins M, Service H, et al. (2002) Genetic analysis of *Pseudomonas aeruginosa* isolates from the sputa of Australian adult cystic fibrosis patients. *J Clin Microbiol* 40: 2772–2778.
53. Armstrong D, Bell S, Robinson M, Bye P, Rose B, et al. (2003) Evidence for spread of a clonal strain of *Pseudomonas aeruginosa* among cystic fibrosis clinics. *J Clin Microbiol* 41: 2266–2267.
54. O'Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, et al. (2004) Clonal strains of *Pseudomonas aeruginosa* in paediatric and adult cystic fibrosis units. *Eur Respir J* 24: 101–106.
55. Scott F, Pitt TL (2004) Identification and characterization of transmissible *Pseudomonas aeruginosa* strains in cystic fibrosis patients in England and Wales. *J Med Microbiol* 53: 609–615.
56. Chambers D, Scott F, Bangur R, Davies R, Lim A, et al. (2005) Factors associated with infection by *Pseudomonas aeruginosa* in adult cystic fibrosis. *Eur Respir J* 26: 651–656.
57. Lewis DA, Jones A, Parkhill J, Speert DP, Govan JRW, et al. (2005) Identification of DNA markers for a transmissible *Pseudomonas aeruginosa* cystic fibrosis strain. *Am J Respir Cell Mol Biol* 33: 56–64.
58. Jelsbak L, Johansen HK, Frost AL, Thogersen R, Thomsen LE, et al. (2007) Molecular epidemiology and dynamics of *Pseudomonas aeruginosa* populations in lungs of cystic fibrosis patients. *Infect Immun* 75: 2214–2224.
59. Bradbury R, Champion A, Reid DW (2008) Poor clinical outcomes associated with a multi-drug resistant clonal strain of *Pseudomonas aeruginosa* in the Tasmanian cystic fibrosis population. *Respirology* 13: 886–892.
60. Brimicombe RW, Dijkshoorn L, van der Reijden TJ, Kardoes I, Pitt TL, et al. (2008) Transmission of *Pseudomonas aeruginosa* in children with cystic fibrosis attending summer camps in The Netherlands. *J Cyst Fibros* 7: 30–36.
61. van Belkum A (1996) Current trends in typing of bacterial strains for medical purposes. *Zentralbl Bakteriol* 1045: 249–252.
62. Vandamme P, Pot B, Gillis M, de Vos P, Kersters K, et al. (1996) Polyphasic taxonomy, a consensus approach to bacterial systematics. *Microbiol Rev* 60: 407–438.
63. Aoki K (1926) Agglutinatorische einteilung von Pyocyanus-bazillen welche bei verschiedenen menschenerkrankungen nach gewiesen wurden. *Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt 1 Orig* 98: 186–195.
64. Vos P, Hogers R, Bleeker M, Reijans M, van de Lee T, et al. (1995) AFLP: a new technique for DNA fingerprinting. *Nucleic Acids Res* 23: 4407–4414.
65. Janssen P, Coopman R, Huys G, Swings J, Bleeker M, et al. (1996) Evaluation of the DNA fingerprinting method AFLP as a new tool in bacterial taxonomy. *Microbiology* 142: 1881–1893.
66. Savelkoul PHM, Aarts HJM, de Haas J, Dijkshoorn L, Duim B, et al. (1999) Amplified-fragment length polymorphism analysis: the state of an art. *J Clin Microbiol* 37: 3083–3091.
67. Spratt BG, Maiden MCJ (1999) Bacterial population genetics, evolution and epidemiology. *Phil Trans R Soc Lond* 354: 701–710.
68. Cornelis P, Bouia A, Belarbi A, Guyonvarch A, Kammerer B, et al. (1989) Cloning and analysis of the gene for the major outer membrane lipoprotein from *Pseudomonas aeruginosa*. *Mol Microbiol* 3: 421–428.
69. Lim A Jr, De Vos D, Brauns M, Mossialos D, Gaballa A, et al. (1997) Molecular and immunological characterization of OprL, the 18 kDa outer-membrane peptidoglycan-associated lipoprotein (PAL) of *Pseudomonas aeruginosa*. *Microbiology* 143: 1709–1716.
70. De Vos D, Lim A Jr, Pirnay JP, Struelens M, Vandenvelde C, et al. (1997) Direct detection and identification of *Pseudomonas aeruginosa* in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, *oprI* and *oprL*. *J Clin Microbiol* 35: 1295–1299.
71. De Vos D, Bouton C, Sarniguet A, De Vos P, Vauterin M, et al. (1998) Sequence diversity of the *oprI* gene, coding for major outer membrane lipoprotein I, among rRNA group I pseudomonads. *J Bacteriol* 180: 6551–6556.
72. Trias J, Nikaido H (1990) Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 34: 52–57.
73. Trias J, Nikaido H (1990) Protein D2 channel of the *Pseudomonas aeruginosa* outer membrane has a binding site for basic amino acids and peptides. *J Biol Chem* 265: 15680–15684.
74. Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, et al. (2002) Analysis of the *Pseudomonas aeruginosa oprD* gene from clinical and environmental isolates. *Environ Microbiol* 4: 872–882.
75. Meyer JM (2000) Pyoverdines: pigments, siderophores and potential taxonomic markers of fluorescent *Pseudomonas* species. *Arch Microbiol* 174: 135–142.
76. Cornelis P, Hohnadel D, Meyer JM (1989) Evidence for different pyoverdine-mediated iron uptake systems among *Pseudomonas aeruginosa* strains. *Infect Immun* 57: 3491–3497.
77. Meyer JM, Stintzi A, De Vos D, Cornelis P, Tappe R, et al. (1997) Use of siderophores to type pseudomonads: the three *Pseudomonas aeruginosa* pyoverdine systems. *Microbiology* 143: 35–43.
78. de Chial M, Ghysels B, Beatson SA, Geoffroy V, Meyer JM, et al. (2003) Identification of type II and type III pyoverdine receptors from *Pseudomonas aeruginosa*. *Microbiology* 149: 821–831.

79. Tümmler B, Cornelis P (2005) Pyoverdine receptor: a case of positive Darwinian selection in *Pseudomonas aeruginosa*. *J Bacteriol* 187: 3289–3292.
80. Smith EE, Sims EH, Spencer DH, Kaul R, Olson MV (2005) Evidence for diversifying selection at the pyoverdine locus of *Pseudomonas aeruginosa*. *J Bacteriol* 187: 2138–2147.
81. Bodilis J, Ghysels B, Osayande J, Matthijs S, Pirnay JP, et al. (2009) Distribution and evolution of ferrityoverdine receptors in *Pseudomonas aeruginosa*. *Environ Microbiol*. 2009 Apr 21. [Epub ahead of print].
82. Ghysels B, Dieu BT, Beatson SA, Pirnay JP, Ochsner UA, et al. (2004) FpvB, an alternative type I ferrityoverdine receptor of *Pseudomonas aeruginosa*. *Microbiology* 150: 1671–1680.
83. Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, et al. (2003) Secretion of the toxin ExoU is a marker for highly virulent *Pseudomonas aeruginosa* isolates obtained from patients with hospital-acquired pneumonia. *J Infect Dis* 188: 1695–1706.
84. Lin HH, Huang SP, Teng HC, Ji DD, Chen YS, et al. (2006) Presence of the *exoU* gene of *Pseudomonas aeruginosa* is correlated with cytotoxicity in MDCK cells but not with colonization in BALB/c mice. *J Clin Microbiol* 44: 4596–4597.
85. Castric P (1995) *pilO*, a gene required for glycosylation of *Pseudomonas aeruginosa* 1244 pilin. *Microbiology* 141: 1247–1254.
86. Kus JV, Tullis E, Cvitkovitch DG, Burrows LL (2004) Significant differences in type IV pilin allele distribution among *Pseudomonas aeruginosa* isolates from cystic fibrosis (CF) versus non-CF patients. *Microbiology* 150: 1315–1326.
87. Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, et al. (1983) *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. *Infect Immun* 42: 170–177.
88. Pitt TL, MacDougall J, Penketh AR, Cooke EM (1986) Polyagglutinating and non-typable strains of *Pseudomonas aeruginosa* in cystic fibrosis. *J Med Microbiol* 21: 179–186.
89. Penketh A, Pitt T, Roberts D, Hodson ME, Batten JC (1983) The relationship of phenotype changes in *Pseudomonas aeruginosa* to the clinical condition of patients with cystic fibrosis. *Am Rev Respir Dis* 127: 605–608.
90. Zierdt CH, Williams RL (1975) Serotyping of *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis of the pancreas. *J Clin Microbiol* 1: 521–526.
91. Bert F, Lambert-Zechovsky N (1996) Comparative distribution of resistance patterns and serotypes in *Pseudomonas aeruginosa* isolates from intensive care units and other wards. *J Antimicrob Chemother* 37: 809–813.
92. Kobayashi L, Hasegawa M, Miyazaki S, Nishida M, Goto S (1994) *In vitro* and *in vivo* changes of serotype in *Pseudomonas aeruginosa* isolates by anti-pseudomonal drugs. *J Antibiot (Tokyo)* 47: 72–79.
93. Kuzio J, Kropinski AM (1983) O-antigen conversion in *Pseudomonas aeruginosa* PAO1 by bacteriophage D3. *J Bacteriol* 155: 203–212.
94. Speijer H, Savelkoul PH, Bonten MJ, Stobberingh EE, Tjebbe JH (1999) Application of different genotyping methods for *Pseudomonas aeruginosa* in a setting of endemicity in an intensive care unit. *J Clin Microbiol* 37: 3654–3661.
95. Tenover FC, Arbeit RD, Goering RV, Micklesen PA, Murray BE, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 33: 2233–2239.
96. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, et al. (1997) *Pseudomonas aeruginosa*-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. *Infect Immun* 65: 579–586.
97. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, et al. (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *Crit Care Med* 30: 521–528.
98. Feltman H, Schulert G, Khan S, Jain M, Peterson L, et al. (2001) Prevalence of type III secretion genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *Microbiology* 147: 2659–2669.
99. Wareham DW, Curtis MA (2007) A genotypic and phenotypic comparison of type III secretion profiles of *Pseudomonas aeruginosa* cystic fibrosis and bacteremia isolates. *Int J Med Microbiol* 297: 227–234.
100. Ferguson MW, Maxwell JA, Vincent TS, da Silva J, Olson JC (2001) Comparison of the *exoS* gene and protein expression in soil and clinical isolates of *Pseudomonas aeruginosa*. *Infect Immun* 69: 2198–2210.
101. Olson JC, Fraylick JE, McGuffie EM, Dolan KM, Yahr TL, et al. (1999) Interruption of multiple cellular processes in HT-29 epithelial cells by *Pseudomonas aeruginosa* exoenzyme S. *Infect Immun* 67: 2847–2854.
102. Rocha CL, Coburn J, Rucks EA, Olson JC (2003) Characterization of *Pseudomonas aeruginosa* exoenzyme S as a bifunctional enzyme in J774A.1 macrophages. *Infect Immun* 71: 5296–5305.
103. Gallant CV, Raivio TL, Olson JC, Woods DE, Storey DG (2000) *Pseudomonas aeruginosa* cystic fibrosis clinical isolates produce exotoxin A with altered ADP-ribosyltransferase activity and cytotoxicity. *Microbiology* 146: 1891–1899.
104. Kulasekara BR, Kulasekara HD, Wolfgang MC, Stevens L, Frank DW, et al. (2006) Acquisition and evolution of the *exoU* locus in *Pseudomonas aeruginosa*. *J Bacteriol* 188: 4037–4050.
105. De Vos D, de Chial M, Cochez C, Jansen S, Tümmler B, et al. (2001) Study of pyoverdine type and production by *Pseudomonas aeruginosa* isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation pyoverdine-negative mutations. *Arch Microbiol* 175: 384–388.
106. Baysse C, Meyer JM, Plesiat P, Geoffroy V, Michel-Briand Y, et al. (1999) Uptake of pyocin S3 occurs through the outer membrane ferrityoverdine type II receptor of *Pseudomonas aeruginosa*. *J Bacteriol* 181: 3849–3851.
107. Denayer S, Matthijs S, Cornelis P (2007) Pyocin S2 (Sa) kills *Pseudomonas aeruginosa* strains via the FpvA type I ferrityoverdine receptor. *J Bacteriol* 189: 7663–7668.
108. Vauterin L, Vauterin P (2006) Integrated databasing and analysis. In: Stackebrandt E, ed. *Molecular identification, systematics, and population structure of prokaryotes*. Berlin: Springer-Verlag, pp 141–217.
109. Schouls LM, van der Heide HG, Vauterin L, Vauterin P, Mooi FR (2004) Multiple-locus variable-number tandem repeat analysis of Dutch *Bordetella pertussis* strains reveals rapid genetic changes with clonal expansion during the late 1990s. *J Bacteriol* 186: 5496–5505.
110. Ragon M, Wirth T, Hollandt F, Lavenir R, Lecuit M, et al. (2008) A new perspective on *Listeria monocytogenes* evolution. *PLoS Pathog* 4: e1000146. doi:10.1371/journal.ppat.1000146.
111. Lanotte P, Watt S, Mereghetti L, Dartiguelongue N, Rastegar-Lari A, et al. (2004) Genetic features of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients compared with those of isolates from other origins. *J Med Microbiol* 53: 73–81.
112. Pitt TL (2002) Cross infection of cystic fibrosis patients with *Pseudomonas aeruginosa*. *Thorax* 57: 921.
113. Van Daele SG, Franckx H, Verhelst R, Schelstraete P, Haerynck F, et al. (2005) Epidemiology of *Pseudomonas aeruginosa* in a cystic fibrosis rehabilitation centre. *Eur Respir J* 25: 474–481.
114. Allemeersch D, Beumer J, Devleeschouwer M, De Maeyer S, Dony J, et al. (1988) Marked increase of *Pseudomonas aeruginosa* serotype O12 in Belgium since 1982. *Eur J Clin Microbiol Infect Dis* 7: 265–269.
115. Finlay BJ (2002) Global dispersal of free-living microbial eukaryote species. *Science* 296: 1061–1063.
116. Réseau épidémiologique des utilisateurs du système SIR (2001) Are the prolonged carrier and interhospital clonal diffusion of serotype O12 multiresistant *Pseudomonas aeruginosa* connected? *Pathol Biol (Paris)* 49: 620–623.
117. Liu PV, Matsumoto H, Kusama H, Bergan T (1983) Survey of heat-stable, major somatic antigens of *Pseudomonas aeruginosa*. *Int J Syst Bacteriol* 33: 256–264.
118. Livermore DM, Struelens M, Amorim J, Baquero F, Bille J, et al. (2002) Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. *J Antimicrob Chemother* 49: 289–300.
119. Amsterdam D (1991) Susceptibility testing of antimicrobials in liquid media. In: Lorian V, ed (1991) *Antibiotics in laboratory medicine*. Baltimore: Williams & Wilkins, pp 72–78.